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Circulating microRNAs (miRNAs) have emerged as novel biomarkers of diabetes. The 
present study focuses on the role of circulating miRNAs in patients with type 1 diabetes and 
their association with diabetic retinopathy. A total of 29 miRNAs were quantified in serum 
samples (n=300) using a nested case-control study design in two prospective cohorts of the 
Diabetic Retinopathy Candesartan Trial (DIRECT programme): PROTECT-1 and 
PREVENT-1. The PREVENT-1 trial included patients without retinopathy at baseline; the 
PROTECT-1 trial included patients with non-proliferative retinopathy at baseline. Two 
miRNAs previously implicated in angiogenesis, miR-27b and miR-320a, were associated 
with incidence and with progression of retinopathy: the odds ratio per standard deviation 
higher miR-27b was 0.57 (95%CI: 0.40, 0.82; P=0.002) in PREVENT-1, 0.78 (0.57, 1.07; 
P=0.124) in PROTECT-1, and 0.67 (0.50, 0.92; P=0.012) combined. The respective odds 
ratios for miR-320a were 1.57 (1.07, 2.31; P=0.020), 1.43 (1.05, 1.94; P=0.021), and 1.48 
(1.17, 1.88; P=0.001). Proteomics analyses in endothelial cells returned the anti-angiogenic 
protein thrombospondin-1 as a common target of both miRNAs. Our study identifies two 
angiogenic miRNAs, miR-320a and miR-27b, as potential biomarkers for diabetic 
retinopathy.  
 
Keywords: Retinopathy / Angiogenesis / Vascular / Proteomics / Endothelial Cell(s) / 
Biomarkers  
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Recent studies have begun to unveil a powerful and unexpected role of microRNAs 
(miRNAs) in numerous forms of diseases, providing a unique opportunity to translate this 
knowledge into the clinical setting in the form of miRNA-based therapeutics and diagnostics 
(1-2). MiRNAs are small non-coding RNAs with cell-type specific expression patterns that 
orchestrate biological networks by modulating gene expression. MiRNAs form base pairs 
with their target messenger RNAs and mediate gene silencing, often regulating multiple 
proteins within the same biological pathways. Given their importance in angiogenesis, along 
with the technical feasibility in manipulating their function in vivo, vascular miRNAs have 
become central targets for therapeutic manipulation, including diabetes (3).  
Additionally, miRNAs circulate in blood. We have previously performed the first 
systematic analysis of circulating miRNAs in a population-based study (the Bruneck Study) 
and identified distinct miRNA signatures associated with type 2 diabetes (4) and risk of 
myocardial infarction (5). We have also highlighted their platelet origin (6) and applied 
concepts of network topology to explore their biomarker potential (7). Exciting opportunities 
exist to pursue miRNAs as novel biomarkers for risk estimation and patient stratification (8).  
The present study addresses the role of circulating miRNAs in patients with type 1 
diabetes (T1D) and their association to microvascular complications, in particular diabetic 
retinopathy. Our aims were three-fold: First, to evaluate whether miRNA profiles are 
independently associated with retinopathy development and progression in diabetes; Second, 
to quantify the incremental discriminatory power of miRNAs over and above traditional risk 
markers; Third, to conduct experiments using endothelial cells and proteomics profiling to 
provide mechanistic insight.   
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RESEARCH DESIGN AND METHODS 
 
Patient sample. The DIabetic REtinopathy Candesartan Trials (DIRECT) trials have been 
described in detail elsewhere (9). In brief, two randomised, double-blind, parallel-design, and 
placebo-controlled trials (PREVENT-1 and PROTECT-1) were conducted in 309 centers 
worldwide. Both trials assigned patients with normotensive, normoalbuminuric T1D to either 
candesartan 16mg once a day or placebo. Exclusion criteria were eye conditions that 
precluded capture of gradable retinal photographs (i.e., open-angle glaucoma, dense cataract 
obscuring retinal view), stenotic valvular disease, previous history of heart attack or stroke, 
pregnancy, lactation, or renal impairment (serum creatinine ≥110μmol/L for women, 
≥130μmol/l for men). The PREVENT-1 trial included patients without retinopathy at baseline 
(defined as Early Treatment Diabetic Retinopathy Study [ETDRS] scale level 10/10); the 
PROTECT-1 trial included patients with non-proliferative retinopathy at baseline (defined as 
ETDRS scale between 20/10 up to 47/47). For the present study, we used a “nested” case-
control approach. Incident cases were defined as patients who progressed three steps or more 
on the ETDRS scale over the course of the study. Cases were stratum matched with controls, 
on sex, HbA1c categories, and categories of diabetes duration (plus an ETDRS summary score 
in PROTECT-1). These were randomly selected from participants whose ETDRS scale did 
not progress and who remained free of intermittent microalbuminuria to the end of the study 
period. Numbers selected for analysis were 70 cases and 70 controls in PREVENT-1, and 93 
cases and 93 controls in PROTECT-1.  Analysis of miRNAs could not be performed on all 
serum samples. Thus, the number of cases and controls in the present analysis was 62 and 64 
in PREVENT-1 and 81 and 93 in PROTECT-1 (n=300).  
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MiRNA measurements. Total RNA from 200μL of serum samples was prepared using the 
miRNeasy kit (Qiagen) as described previously (4). A fixed volume of 3μl of the 25μL RNA 
eluate was used as input for reverse transcriptase (RT) reactions using Megaplex Primer 
Pools (Human Pools A v2.1, Life Technologies). RT reaction products were further amplified 
using the Megaplex PreAmp Primers (Primers A v2.1). Taqman miRNA assays were used to 
assess the expression of individual miRNA. 0.5μL diluted pre-amplification product were 
combined with 0.25μL Taqman miRNA Assay (20x) (Life Technologies) and 2.5μL Taqman 
Universal PCR Master Mix No AmpErase UNG (2x) to a final volume of 5μL. qPCR was 
performed on an Life Technologies Viia7 thermocycler at 95°C for 10 min, followed by 40 
cycles of 95°C for 15 sec and 60°C for 1 min. All samples were run in duplicates. Relative 
quantification was performed using the DataAssist v3.01 (Life Technologies). For 
normalization purposes, the average of all miRNA targets displaying Ct<32 cycles or an 
exogenous miRNA (cel-miR-39) spiked-in during RNA extraction were applied, as described 
previously (5).  
 
Transfection. Human umbilical vein endothelial cells (HUVECs) were cultured as described 
previously (10) and seeded at 60-70% confluency on the day before transfection. Cells were 
washed in serum-free Dulbecco’s Modified Eagle Medium (DMEM) and replaced with M199 
containing EC supplement without antibiotics or serum. Human retinal microvascular 
endothelial cells (HRECs, obtained from Cell systems, Kirkland US) were seeded on CSC 
attachment factor (4Z0-210) and cultured in CSC complete media (4Z0-500). Prior to 
transfection HRECs were washed with CSC Serum Free Medium without antibiotics (SF-
4Z0-500). MiRNA mimics or nontargeting mimic control (MC) were transfected at a final 
concentration of 50nmol/L using Lipofectamine
TM
 RMAiMAX (Invitrogen) according to the 
manufacturer’s recommendations (11). 
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Proteomic profiling of the endothelial secretome. HUVECs were carefully washed in 
serum-free medium and then incubated twice in fresh serum-free M199 for 30 min. Cells 
were stimulated in phorbol 12-myristate 13-acetate (PMA, 50nmol/L) containing M199 
medium for 45 min and analysed by mass spectrometry as described previously (10). The 
conditioned medium was collected, centrifuged at 1000rpm for 5 min and concentrated using 
Amicon 3kD MWCO 15ml spin columns (Millipore) to 135µL. Then 0.5M Tris, 1% SDS, 
pH 8.8 (15µL) and 100mmol/L of DTT reducing agent (7.8µL) were added under agitation 
for 1 hr at 55C, followed by incubation with 500mmol/L iodoacetamide (8.3µl) for 1 hr 
before precipitation with cold acetone (-20C) overnight at -20C. Samples were centrifuged 
(14000rpm, 10 min), the supernatant was discarded and the protein pellet left to air-dry. 
Pellets were re-suspended in 0.1mol/L, pH 8.5, triethylammonium bicarbonate (100µL) and 
incubated at 37C under agitation for 30 min. Proteins were digested in 0.4µg/µl trypsin 
(1µL) overnight at 37C. The reaction was stopped by addition of 10% formic acid (50µL). 
Peptide samples were purified using C18 spin columns (Thermo-Scientific). The eluate was 
kept at -80C before freeze drying (Christ Alpha 1-2 LD Freeze Dryer) under vacuum at -
55C. The samples were re-suspended in 2% acetonitrile, 0.1% formic acid (20µl) and 
analyzed by reverse-phase nanoflow high performance liquid chromatography (Acclaim® 
PepMapC18, 3 µmole/L, 100Å, 50cm x 75µm inner diameter column (Thermo Scientific) 
interfaced with a Q Exactive Plus Orbitrap mass spectrometer (Thermo Scientific). Each 
sample was separated at a flow rate of 0.3 µl/min over 4 hrs as follows: 0-10 min / 2%-
10%B, 10-200 min / 10%-30%B, 200-210 min / 30%-40%B, 210-220 min / 99%B, 220-240 
min / 2%B, where A=0.1% formic acid in ddH2O and B=80% acetonitrile, 0.1% formic acid 
in ddH2O. Samples were subject to a full MS scan over m/z range from 350-1600, whereby 
the 15 most abundant peaks were selected for tandem mass spectrometry and fragmented by 
higher energy collisional dissociation.  
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Database search. Raw data were analysed by Mascot and Sequest HT algorithms (Proteome 
Discoverer 1.4) to identify proteins against Swissprot protein database (version 201401) with 
taxonomy set to all entries, precursor mass tolerance 10 ppm, fragment mass tolerance 20 
mmu, oxidation of methionine as a variable modification and carbamidomethylation of 
cysteine as a static modification, and a maximum of two missed cleavage sites permitted. 
Search results were loaded onto Scaffold software (version 4.3), where a protein probability > 
99%, a peptide probability > 95% and a minimum number of two peptides per protein were 
applied as filters to generate the list of identified proteins. 
 
Luciferase reporter assays. The 3’ untranslated region of the human NRP1 and SEMA6A 
harboring a putative binding site for miR-320a and miR-27b respectively, were cloned into 
the XhoI and PmeI linkers of the dual-luciferase reporter vector psiCheck2 (Promega). The 
following primer sets were used:  
NPR; F: TTCAATGAGTATGGCCGACA,  
NPR; R: GGATTTCGCTCAGTTTCC, 
SEMA6A; F: CGCACAGAGGTGAACAGAAA, 
SEMA6A; R: GCCCAACATGGCATTTATCT.  
The reporter constructs (100ng) were transfected together with their respective miRNA 
mimics (50nmol/L) or MC in triplicate into HUVECs, previously plated (post-12 hrs) in 6-
well plates using lipofectamine RNAiMAX (Invitrogen) as described above. After 48 hrs, 
cells were harvested in 200μL Glo Lysis Buffer (Promega) and the activities of both Renilla 
and firefly were measured. 30μL of each lysate were analysed using Dual-Glo Luciferase 
reagents (Promega). Renilla luciferase activity was normalised to constitutive firefly 
luciferase activity for each well. 
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Enzyme-linked immunosorbent assay (ELISAs). Thrombospondin-1 levels in the 
conditioned media were determined using the Human Thrombospondin-1 Quantikine ELISA 
Kit (Bio-Techne) according to the manufacturer’s instruction. 
 
Statistical analysis. MiRNA values were log-transformed for analysis. Pair-wise correlations 
between miRNAs and other markers were assessed using Pearson correlation coefficients in a 
pooled dataset of 145 controls, and plotted with the R package ‘corrplot’ using hierarchical 
clustering and the single linkage method. We analysed the association of miRNAs with 
incident retinopathy in two steps. First, to identify the miRNA subset with the highest 
prognostic ability for future retinopathy, we used a L1-penalized logistic regression 
technique. This method helps prevent overfitting of collinear and high-dimensional data and 
implements the ‘least absolute shrinkage and selection operator’ (LASSO) algorithm, 
shrinking regression coefficients towards zero relative to the maximum likelihood estimates. 
The amount of shrinkage is determined by the tuning parameter λ1, which is progressively 
increased up to the value that shrinks all regression coefficients to zero. We estimated the 
optimal tuning parameter λ1 as the median of ten thousand 5-fold likelihood cross-
validations. Plots of beta coefficients (y-axis) versus λ1 (x-axis) were generated using the R 
package ‘penalized’. Sensitivity analyses were conducted that (i) standardized miRNA 
concentrations to a global Ct average (instead of to Cel miR-39) and (ii) excluded participants 
from analysis with diabetic nephropathy or microalbuminuria. Because the LASSO method 
allows assessment of relevance and robustness of individual explanatory variables but 
produces biased estimates of beta coefficients, we fitted, as a second step, ‘traditional’ 
logistic regression models for identified miRNAs. Analyses were adjusted for age, sex and 
diastolic blood pressure, and conducted separately for the two trials. A pooled estimate of 
association was calculated with random-effects meta-analysis. Between-study heterogeneity 
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was assessed by the I
2
 statistic (12). Regarding the experimental studies, results are presented 
as the mean±S.E.M. For results from transfected ECs, paired or unpaired Student t-test, one-
way ANOVA with Dunnetts or Tukey’s post-hoc analysis, and two-way ANOVAs were 
performed using GraphPad prism 5 software. With allowance for loss due to missing miRNA 
measurement, our sample size allowed us to detect a difference in retinopathy incidence and 
in progression in association with a standardized difference of 0.4 and 0.5 respectively for 
any given miRNA signal with 80% power and 5% significance. Analysis was performed 




Associations of miRNAs with incidence and progression of retinopathy in the 
DIRECT trials. From the PREVENT-1 and PROTECT-1 trials of a total of 3326 participants 
with T1D, we selected 62 patients with incident diabetes retinopathy, 93 patients with 
progressive diabetes retinopathy, and 145 matched controls. Supplementary Table 1 
compares clinical characteristics of participants selected for the nested case-control analysis 
and those not selected. A panel of 29 miRNAs, of which some were previously shown to be 
associated with T2D (4) and CVD (5), were measured in serum and values were standardized 
to an exogenous spike-in normalization control, Cel miR-39. Baseline characteristics of study 
participants are summarized in Table 1. The ratio of males to females, and mean diabetes 
duration, was similar in cases and controls within each trial, as anticipated due to matching.  
Mean HbA1c, however, was a little higher in controls, reflecting the fact that cases and 
controls were stratum, rather than individually matched by HbA1c. Differences in age and 
blood pressure levels were also observed in the two study populations. The complex 
correlation patterns of serum miRNAs and baseline characteristics are depicted in Fig. 1. 
MiRNAs emerged to be highly correlated with each other, but largely independent from other 
characteristics such as age, duration of diabetes, blood pressure and HbA1c. 
We conducted penalized logistic regression analyses adjusted for age, sex and 
diastolic blood pressure were conducted to identify and evaluate the association of miRNAs 
with incidence and progression of diabetic retinopathy (Fig. 2, Supplementary Fig. 1). The 
descriptive tables in Fig. 2 show the direction of association and the percentage of cross-
validated models that included the respective miRNA. The following miRNAs were 
identified in descending order of importance: miR-27b, miR-320a, miR-454, and miR-28-3p 
in PREVENT-1; and miR-320a, miR-122, miR-221, and miR-27b in PROTECT-1. 
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Generally, these miRNAs were more commonly selected for inclusion in cross-validated 
models for incidence than for progression of diabetic retinopathy (>90% vs. >10%). Results 
for all 29 individual miRNAs are provided in Supplementary Fig. 2, but should be 
interpreted with caution in light of multiple testing and type-1 error. 
Since combinations of miRNAs can be superior to individual miRNAs (4, 5, 7), we 
then performed ‘traditional’ logistic regression for the two miRNAs most consistently 
associated with incidence and progression of diabetic retinopathy: miR-27b and miR-320a. 
Fig. 3 shows estimates of associations for miR-27b and miR-320a adjusted for each other, 
age, sex and diastolic blood pressure. The odds ratio per standard deviation higher miR-27b 
was 0.57 (95%CI: 0.40, 0.82; P=0.002) in PREVENT-1, 0.78 (0.57, 1.07; P=0.124) in 
PROTECT-1, and 0.67 (0.50, 0.92; P=0.012) combined. The respective odds ratios for miR-
320a were 1.57 (1.07, 2.31; P=0.020), 1.43 (1.05, 1.94; P=0.021), and 1.48 (1.17, 1.88; 
P=0.001). Qualitatively similar results were observed in analyses that (i) standardized 
miRNA levels to a Ct-average of all miRNAs (instead of standardization to spiked in Cel 
miR-39, Supplementary Fig. 3); (ii) excluded cases with incident microalbuminuria 
(Supplementary Fig. 3); (iii) used different levels of adjustment (unadjusted; age, sex and 
systolic blood pressure or HbA1c); or (iv) omitted outliers of the miRNA distributions. 
Supplementary Fig. 4 summarizes raw values of miR-27b and miR-320a for cases and 
controls. Addition of information on miR-27b and miR-320a to a model a panel of variables 
associated with disease risk (i.e., age, sex, duration of diabetes, diastolic blood pressure, and 
level of HbA1c) improved the area under the receiver operating curve by 0.087 for 
PREVENT-1 (P=0.027) and by 0.034 for PROTECT-1 (P=0.214) (Supplementary Fig. 5). 
Expression of miRNAs in endothelial cells. A PCR comparison was conducted to 
compare the endogenous expression of miR-27b and miR-320a to abundant endothelial 
miRNAs (miR-126 and miR-126* or miR-126-3p and miR-126-5p, respectively). There was 
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no major difference in the endogenous miRNA expression of miR-27b, miR-320a, miR-126-
3p  and miR-126-5p between four different types of ECs: human saphenous vein endothelial 
cells (HSaVEC), human aortic endothelial cells (HAoEC), human retinal endothelial cells 
(HRECs) and HUVECs (Supplementary Table 2). Notably, miR-320a was consistently 
more abundant in endothelial cells than miR-27b. Next, mimics for miR-27b and miR-320a 
were co-transfected with luciferase reporter constructs containing putative binding site of two 
confirmed target proteins for miR-27b and miR-320a: semaphorin-6A (SEMA6A) and 
neuropilin-1 (NRP1), respectively. SEMA6A is a negative regulator of MAPK signaling, 
known to increase transcription of angiogenic effector genes (14). NRP1 is a co-receptor for 
VEGF and semaphorin, promoting EC proliferation and microvessel density (15). 48 hrs after 
transfection, luciferase activity was found to be decreased by approximately 30% and 40% in 
SEMA6A and NRP1, respectively (Fig. 4A, B). Thereby the functionality of miRNA mimics 
was confirmed through silencing expression of known targets. 
Proteomics for miRNA target identification. We have demonstrated recently that 
direct and indirect targets can be identified in a broader proteomics screen, including targets 
that would not have been anticipated based on current bioinformatics prediction models (11, 
16). To complement our clinical studies, we used a proteomics approach to identify putative 
protein targets of miR-27b and miR-320a in the secretome of endothelial cells. HUVECs 
were stimulated with PMA to induce exocytosis of Weibel-Palade bodies, an endothelial-cell 
specific storage organelle, allowing for protein analysis by mass spectrometry. Among over 
650 proteins identified (Supplementary Table 3), only thrombospondin-1 (TSP-1) showed 
differential secretion from both miR-27b and miR-320a transfected endothelial cells, relative 
to control transfected cells (Fig. 4C, D). The proteomics data were independently validated 
by ELISA (Fig. 5A). Similar results were obtained in HRECs following miR-27b or miR-
320a overexpression (Fig. 5B). An alignment of the thrombospondin-1 gene (THBS-1) 
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mRNA region with the sequence of miR-320a and miR-27b is shown in Fig. 6A. The vertical 
bars and bold characters indicate sequences of the miR-320a and miR-27b binding site of the 
THBS-1 target gene. As expected for direct miRNA targets, there was complementarity 
between the miR-27b seed-matching sequence and the 3′-UTR region of the THBS-1 target 
gene. According to one algorithm (miRWalk), TSP-1 was also predicted as a target for miR-
320a. The putative seed binding region, however, was within the coding region of the THBS-
1 gene. To further confirm the functionality of these predicted interactions, we fused the 
putative binding regions within the THBS-1 target gene to a luciferase reporter vector. Co-
expression of synthetic miR-27b, but not miR-320a decreased THBS-1 reporter activity (data 
not shown), confirming TSP-1 as a direct target of miR-27b (17) and an indirect target of 





Using data from two independent prospective cohorts, we identified miR-27b and miR-320a 
as potential biomarkers for new onset or progression of retinopathy in patients with T1D. 
Both miR-27 and miR-320a have previously associated with metabolic syndrome and type 2 
diabetes (18) and implicated in angiogenesis, providing a mechanistic underpinning for the 
observed association with diabetic retinopathy in the DIRECT cohort (9). 
Retinopathy in T1D. Retinopathy remains the most frequent, and most feared 
complication of T1D (19). It is associated with elevated risks of other diabetes complications, 
notably nephropathy and cardiovascular disease (20). Although acknowledged as a vascular 
phenomenon, the only intervention proven to date to reduce onset or progression of 
retinopathy is tight glycaemic control. This is difficult to achieve, and is associated with 
elevated risks of hypoglycaemic episodes. Significant numbers of individuals with T1D 
continue to progress to severe, possibly sight-threatening disease even in the presence of 
good glycaemic control. There is therefore a need to discover novel biomarkers, which 
identify individuals at high risk of progressive retinopathy, and targets for therapeutic 
intervention.  
MiRNAs in T1D. MiRNAs may offer distinct advantages over other biomarkers (8): 
Unlike messenger RNAs, miRNAs are stable in blood. As nucleic acids, miRNAs can be 
measured by qPCR methodology allowing the multiplexing of several miRNAs in a single 
experiment. Thus far, the role of miRNAs in diabetic retinopathy progression has been 
assessed in small animal models (21-26). Moreover, a miRNA dependent cross-talk between 
HIF1α and VEGF was reported in the diabetic retina (27). In this study, we show that miR-
320a and miR-27b are associated with new onset or progression of retinopathy in patients 
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with T1D. These findings were unaltered by excluding participants with incident persistent or 
intermittent microalbuminuria at any time during the follow up. 
Mechanistic links to angiogenesis. Besides its potential prognostic and diagnostic 
value, miRNAs may participate in an unexplored mechanism contributing to retinopathy in 
patients with T1D. Several miRNAs can target the same effector. Diverse miRNAs can also 
act cooperatively or redundantly to regulate the effectors of the same biological process. 
MiR-320a regulates glycolysis and represses angiogenic factors, including Flk1, VEGFc, 
IGF-1, IGF-1R and FGF (28-29). MiR-320a has also been implicated in tumor angiogenesis 
by silencing neuropilin-1 (30). MiR-27b is thought to promote angiogenesis by targeting anti-
angiogenic genes (31), including the transmembrane protein, semaphorin-6A. The miR-23/-
27/-24 gene clusters are enriched in endothelial cells and highly vascularized tissues (32). 
MiR-27b orchestrates endothelial tip cell formation (33-34). By analysing protein targets of 
miR-27b and miR-320a in endothelial cells, we obtained a more comprehensive depiction of 
the interactions and regulatory feedback loops between angiogenic proteins and our candidate 
miRNAs.  
Proteomics approach for miRNA target identification. The “targetome” of most 
miRNAs remains an unexplored aspect of current biology. Currently, the available miRNA 
target prediction tools are based on an incomplete understanding of miRNA target 
recognition and miRNA efficacy. Bioinformatic methodologies reveal numerous putative 
targets, but only 1 out of 5 of the in silico predictions is correct and experimental 
confirmation is essential. Proteomics methods can be useful for identifying miRNA targets at 
the protein level in addition to the use of bioinformatics prediction algorithms. We have 
pursued a proteomics approach to compare the effects of miR-27b and miR-320a on the 
secretome of endothelial cells (10). TSP-1 was returned as a common target of both miR-27b 
and miR320a (35). TSP-1 is an extracellular matrix protein, which inhibits EC proliferation, 
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migration and angiogenesis (36). Its anti-angiogenic effect is mediated through an interaction 
with VEGF, specifically via inhibition of VEGF receptor-2 activation through engaging its 
receptor CD47 (37). This has further been supported in-vivo, specifically in the eye: depletion 
of TSP-1 resulted in corneal neovascularisation in mice (38). Of particular significance to 
diabetic retinopathy, a biphasic response of TSP-1 mediated through VEGF occurred in 
microvascular cells in the ischemic retina (39). This response tightly regulates VEGF and 
therefore indicates a potential negative feedback mechanism of VEGF-induced angiogenesis 
through TSP-1 (39). By now, several studies have implicated TSP-1 in pathological 
angiogenesis in the retina (40-42). TSP-1 has been shown to inhibit neovascularisation in 
diabetic mice (43). Moreover, miR-27b rescued impaired angiogenesis via TSP-1 suppression 
(17). Our findings confirm that miR-27b directly suppresses reporter activity for TSP-1. In 
contrast, miR-320a has an indirect effect on TSP-1 secretion. 
Strengths and limitations of the study. Our study was prospective and hence 
measured miRNA levels before occurrence of the disease outcome. Using a nested case-
control approach, we identified 155 participants with retinopathy incidence/progression 
among DIRECT trial participants (overall n=3326) and compared miRNA profiles to those of 
matched controls. Associations were independent of established risk factors for diabetic 
retinopathy, including age, sex, HbA1c, diabetes duration and blood pressure, and were 
further underpinned by our biologically-plausible finding from the proteomics analysis that 
both miRNAs target thrombospondin-1. Still, whether miR-27b and miR-320a are causally 
involved in diabetes retinopathy or a marker of this disease remains to be clarified. The 
identified miRNAs are not retina specific. The changes in miR-27b and miR-320a may reflect 
a systemic predisposition for pathological angiogenesis. The cause for the differential 
regulation of circulating levels of miR-27b and miR-320a is currently unclear. For many 
biomarkers, the cellular origin remains uncertain. For example, both endothelial cells as well 
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as platelets secrete TSP-1. Measuring its circulating levels does not reveal how much of TSP-
1 is endothelial- or platelet-derived. The same limitation applies to miRNAs that are not 
tissue specific and detected in the circulation. Both miR-320a and miR-27b are also present 
in platelets (6). The opposing directionality of the association of miR-27b and miR-320a with 
diabetic retinopathy could hint to a different cellular origin of these two circulating miRNAs, 
i.e. miR-320a is secreted at much higher levels from endothelial cells than miR-27b. Further 
studies are required to provide an in depth understanding of their cellular origin and to test 
the diagnostic or therapeutic potential of these two circulating miRNAs in diabetic 
retinopathy. We measured miRNA levels only at baseline and hence could not assess nor take 
into account within-person variability of the miRNAs over time. Finally, model selection and 
parameter estimation were performed on the same dataset without adjustment, which may 
lead to an overestimation of the strength of association obtained and underestimation of 
confidence limits.  
Conclusions. Understanding how circulating miRNAs could be harnessed for 
assessing the risk of retinopathy in T1D is an essential area of research. Our data in the 
DIRECT trials show that miR-320a and miR-27b are associated with new onset and 
progression of retinopathy. Besides identifying circulating miRNAs associated with 
retinopathy, we also interrogated the targets of miR-27b and miR-320a in endothelial cells 
using a proteomics approach. Taken together, our study is the first to identify miRNA 
biomarkers for retinopathy in two independent cohorts. These findings await confirmation in 
larger studies but our two lead miRNAs may have clinical utility given their established links 
to angiogenesis, including the translational control of TSP-1 by miR-27b and its reduced 
endothelial secretion by miR-320a. 
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FIG. 1. Pair-wise Pearson correlation coefficients of serum miRNA concentrations and 
other markers. Abbreviations: DBP, diastolic blood pressure; HbA1c, haemoglobin A1c; 
SBP, systolic blood pressure; T1DM, type 1 diabetes mellitus; UAER, urinary albumin 
excretion rate.  
 
FIG. 2. Penalized logistic regression analysis of the associations of 29 serum miRNA 
concentrations with diabetic retinopathy. Association with incident diabetic retinopathy in 
PREVENT-1 (A). Association with progression of diabetic retinopathy in PROTECT-1 (B).  
Models included age, sex and diastolic blood pressure as unpenalized covariates. The graph 
shows beta coefficients for different levels of penalization (λ1, estimated in 100 steps) and is 
truncated at a λ1 of 3, hence not all measured miRNAs are plotted. The black dashed line 
indicates the optimal tuning parameter λ1 evaluated using ten thousand 5-fold likelihood 
cross-validations. The descriptive table shows the direction of association and the percentage 
of cross-validated models that included the respective miRNA. 
 
FIG. 3. Standard logistic regression analysis and meta-analysis of the association of 
miR-27b and miR-320a with diabetic retinopathy and TSP-1 as common target in 
endothelial cells. Association of miR-27b and miR-320a with diabetic retinopathy in 
PREVENT-1, PROTECT-1, and both studies combined. Associations of miR-27b and miR-
320a with diabetic retinopathy were adjusted for each other, plus age, sex, and diastolic blood 
pressure. Standard deviations were defined in controls. Study-specific results were combined 




FIG. 4. Proteomics for miRNA target identification. Luciferase reporter assays to confirm 
functional miRNA mimics. Suppression of semaphorin-6A (A), a known target of miR-27b, 
and neuropilin-1 (B), a target of miR-320a. Spectral counts of thrombospondin-1 as 
quantified by mass spectrometry in the secretome of miR-27b (C) and miR-320a (D) 
transfected endothelial cells compared to mimic controls. Error bars represent SEM. * 
denotes p<0.05 in 3 independent experiments, ** P<0.01. 
 
FIG. 5. Validation of the proteomics findings by ELISA. Reduced secretion of 
thrombospondin-1 (TSP1) in the endothelial secretome upon transfection with mimics of 
miR-27b and miR-320a. (A) HUVECs following 45min of PMA stimulation in serum-free 
medium and (B) HRECs following overnight serum deprivation in the presence of endothelial 
supplements. * P<0.05.  
 
FIG. 6. Angiogenic miRNAs. Alignment of thrombospondin-1 (THBS-1) mRNA region 
with miR-320a and miR-27b (A). Relative abundance of miR-320a and miR-27b in 
endothelial cells (EC) and suppression of TSP1 secretion as a shared molecular pathway (B). 
Circulating miRNA changes in patients with T1D and retinopathy, however, may represent 
markers of a milieu that is conducive to pathological angiogenesis rather than a local release 
from the retina.  
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Table 1. Baseline characteristics of the study populations. 
 















Mean (SD), median [IQR]  
or count (%)   
Mean (SD), median [IQR]  
or count (%)  
        
Age at randomisation, years 31.1 (8.1) 27.7 (8.1) 0.02   31.5 (9.1) 31 (8.5) 0.7 
Male sex 33 (53%) 37 (58%) 0.7 
 
58 (62%) 42 (52%) 0.2 
Duration of diabetes, years 7.3 (3.8) 7.3 (3.6) 1.0 
 
10.9 (4.0) 10.6 (4.0) 0.7 
Systolic blood pressure, mmHg 116 (9.1) 119 (9.6) 0.04 
 
117 (10.8) 118 (8.9) 0.7 
Diastolic blood pressure, mmHg 72 (7.7) 73 (6.5) 0.3 
 
72.7 (7.0) 75 (6.4) 0.02 
HbA1c, %
†
 8.9 (1.5) 9.2 (1.8) 0.4 
 
8.9 (1.2) 9.4 (1.5) 0.05 
UAER, µg/min 4.8 [3.3, 6.5] 4.3 [3.5, 6.0] 0.4   5.0 [3.0, 6.5] 5.0 [3.5, 9.5] 0.2 
WHR all 0.81 (0.07) 0.83 (0.09) 0.08  0.85 (0.08) 0.82 (0.08) 0.1 
WHR men 0.84 (0.07) 0.88 (0.09) 0.03  0.88 (0.07) 0.88 (0.07) 0.4 
WHR women 0.77 (0.05) 0.77 (0.05) 0.9  0.78 (0.07) 0.77 (0.07) 0.5 
Creatinine, µmol/l 89.7 (13) 90.0 (14) 0.9  88.1 (13.8) 86.7 (14.1) 0.6 
GFR*, ml/min/1.73m
2
 88 [75,107] 90 [79,105] 0.8  92 [77,107] 94 [80,104] 0.8 
GFR**, ml/min/1.73m
2
 83 [71,96] 83 [73,98] 0.8  86 [73,100] 88 [75,96] 0.6 
HDL cholesterol, mmol/l 1.7 (0.3) 1.7 (0.4) 0.6  1.7 (0.4) 1.8 (0.4) 0.07 
Total cholesterol, mmol/l 4.7 (1.1) 4.9 (0.9) 0.5  5.1 (1.1) 4.9 (0.8) 0.2 
Insulin dose, U/kg/day 0.77 (0.21) 0.69 (0.24) 0.07  0.81 (0.30) 0.71 (0.20) 0.01 
eGDR*** mg/kg/min 9.2 (1.3) 9.0 (1.4) 0.4  8.6 (1.3) 9.1 (1.3) 0.02 
Never smoker 34 (55) 47 (73)   50 (54) 54 (67)  
Ex smoker 7 (11) 2 (3)   5 (5) 8 (10)  
Current smoker 21 (34) 15 (24) 0.02  38 (41) 19 (23) 0.08 
        
 
Abbreviations: HbA1c, haemoglobin A1c; IQR, interquartile range; SD, standard deviation; UAER, 
urinary albumin excretion rate; WHR, waist hip ratio; HDL, high-density lipoprotein. *P values were 
calculated using Fisher's exact tests for categorical variables, two-group t-tests for continuous 
normally-distributed variables, or Wilcoxon rank-sum tests for continuous left-skewed variables.  
 
GFR* CKD-EPI (44)  
GFR** MDRD4 (45)    














Angiogenic MicroRNAs Linked to Incidence and Progression  
of Diabetic Retinopathy in Type 1 Diabetes 
 
 
Anna Zampetaki1*, Peter Willeit1,2,3*, Simon Burr1, Xiaoke Yin1, Sarah R. Langley1, 




1 King’s British Heart Foundation Centre, King’s College London, UK 
2 Department of Public Health and Primary Care, University of Cambridge, UK 
3 Department of Neurology, Medical University of Innsbruck, Austria 
4 Department of Ophthalmology and Visual Sciences, University of Wisconsin, US 
5 Steno Diabetes Centre, University of Copenhagen, DK 




Supplementary Table: 3 
Supplementary Figures: 5 
 
 2 
Supplementary Table 1.  










 Included Not 
included 




Mean (SD), median [IQR]  
or count (%) 
 
  
Mean (SD), median [IQR]  
or count (%) 
        
N 126 1295   174 1731  
Age (yr) 29.4 (8.2) 29.8 (8.1) 0.6  31.2 (8.7) 31.7 (8.4) 0.4 
Men 70 (56) 735 (57) 0.8  100 (57) 999 (57) 1.0 
Duration (yr) 7.3 (3.7) 6.7 (3.9) 0.06  10.7 (4.0) 11.0 (4.3) 0.5 
HbA1c % 9.0 (1.7) 8.1 (1.7) <0.0001  9.2 (1.4) 8.4 (1.6) <0.0001 
Systolic BP mmHg 118 (10) 116 (10) 0.1  118 (10) 117 (10) 0.5 










BMI kg/m2 23.9 (3.4) 23.9 (3.3) 0.9  24.4 (3.4) 24.7 (3.6) 0.3 
WHR all 0.82 (0.08) 0.83 (0.09) 0.3  0.84 (0.08) 0.84 (0.09) 0.3 
WHR men 0.86 (0.08) 0.87 (0.08) 0.5  0.88 (0.07) 0.89 (0.07) 0.3 
WHR women 0.77 (0.05) 0.78 (0.07) 0.4  0.78 (0.07) 0.79 (0.07) 0.4 
Creatinine µmol/L 89.8 (13.4) 89.8 (14.1) 1.0  87.4 (13.3) 91.1 (13.7) 0.01 
GFR* ml/min/1.73m
2
 91 (20) 91 (20) 0.8  93 (19) 89 (19) 0.002 
GFR** ml/min/1.73m
2
 86 (23) 86 (22) 0.9  88 (21) 83 (19) 0.002 
HDL cholesterol 
mmol/l 
1.7 (0.3) 1.7 (0.4) 0.7  1.7 (0.4) 1.7 (0.4) 0.2 
Total cholesterol 
mmol/l 
4.8 (1.0) 4.7 (1.0) 0.5  5.0 (1.0) 4.8 (0.91) 0.02 
Never smoker 81 (64) 880 (68)   104 (60) 1136 (66)  
Ex smoker 9 (7) 88 (7)   13 (7) 149 (9)  
Current smoker 36 (29) 327 (25) 0.6  57 (33) 446 (25) 0.05 
        
 
Abbreviations: HbA1c, haemoglobin A1c; IQR, interquartile range; SD, standard deviation; 
UAER, urinary albumin excretion rate; BMI, body mass index; WHR, waist hip ratio; HDL, 
high-density lipoprotein. *P values were calculated using Fisher's exact tests for categorical 
variables, two-group t-tests for continuous normally-distributed variables, or Wilcoxon rank-
sum tests for continuous left-skewed variables.  
 
GFR* CKD-EPI Levey AS, Stevens LA, Schmid CH.  Ann Int Med 2009; 150; 604-12 
 
GFR** MDRD4  Levey AS, Coresh J, Greene T Clin Chem 2007; 53; 766-72 
 
eGDR*** estimated glucose disposal rate. From Williams KV, Erbey JR, Becker D. Diabetes 
2000; 49; 626-32 
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Supplementary Table 2.  
Endogenous miRNA expression in different endothelial cell types. 
 
QPCR analysis demonstrated comparable levels of endogenous miRNA expression, miR-
27b, miR-126-3p, miR-126-5p (miR-126*) and miR-320a among four different endothelial 
cells: human retinal endothelial cells (HRECs), human saphenous vein endothelial cells 
(HSaVEC), human aortic endothelial cells (HAoEC) and human umbilical vein endothelial 





Ct Mean, (SD) 
 











HSaVEC 29.9 (0.53) 17.16 (0.28) 20.67 (0.85) 23.26 (0.34) 
HAoEC 29.86 (0.26) 17.34 (0.35) 20.63 (0.41) 23.15 (0.19) 
HUVEC 29.87 (0.38) 17.07 (0.12) 20.61 (0.28) 22.92 (0.19) 
 
 
Abbreviations: Ct, cycle threshold; SD, standard deviation; HREC, human retinal endothelial 
cells; HSaVEC, human saphenous vein endothelial cells; HAoEC, human aortic endothelial 
cells; HUVEC, human umbilical vein endothelial cells. 
Supplementary Table 3.  
Mass spectrometry spectral counts for proteins identified in conditioned media of transfected endothelial cells (n=4) 
 
   Mimic Control (Mc) Mimic for miR-27b   Mimic for miR-320a   




Weight 1 2 3 4 1 2 3 4 Fold   P-value 1 2 3 4 Fold  P-value 
 
Serum albumin  ALBU_BOVIN 69 kDa 1160.7 866.3 699.2 303.0 1071.9 1115.3 251.4 512.5 1.0 0.946 1226.2 501.2 1331.4 481.5 1.2 0.676 
Serotransferrin  TRFE_BOVIN 78 kDa 224.9 207.7 174.4 69.9 313.9 249.8 57.0 104.7 1.1 0.869 275.1 110.9 320.4 105.4 1.2 0.628 
Alpha-2-HS-glycoprotein FETUA_BOVIN 38 kDa 181.4 134.7 120.5 69.1 173.6 180.9 58.0 99.8 1.0 0.966 208.0 99.5 246.8 108.8 1.3 0.404 
Alpha-2-macroglobulin A2MG_BOVIN 168 kDa 172.3 143.8 115.6 50.7 181.9 167.9 34.8 59.1 0.9 0.840 201.2 88.9 202.7 80.5 1.2 0.616 
Actin, cytoplasmic type 5  
ACT5_CHICK 
(+8) 42 kDa 119.7 116.4 140.5 120.6 59.3 120.6 111.7 194.6 1.0 0.929 105.4 143.5 79.3 131.2 0.9 0.571 
Alpha-1-antiproteinase A1AT_BOVIN 46 kDa 152.3 108.4 100.5 32.4 189.1 152.2 35.9 51.7 1.1 0.852 173.8 67.6 182.3 63.1 1.2 0.592 
Vimentin VIME_HUMAN 54 kDa 74.4 74.2 73.3 89.0 27.2 73.2 67.8 141.7 1.0 0.993 37.0 75.2 32.8 88.0 0.7 0.255 
Alpha-fetoprotein  FETA_BOVIN 69 kDa 76.2 71.9 70.8 14.7 129.8 96.2 22.1 27.1 1.2 0.746 105.4 38.7 129.1 31.5 1.3 0.558 
Heat shock cognate 71 
kDa protein  
HSP7C_BOVIN 
(+1) 71 kDa 27.2 42.2 46.6 49.3 7.8 51.7 65.3 57.9 1.1 0.771 34.2 53.9 18.1 45.7 0.9 0.730 
Fetuin-B  FETUB_BOVIN 43 kDa 45.3 65.1 40.0 14.7 56.6 66.0 13.1 17.2 0.9 0.864 93.1 28.9 82.6 24.9 1.4 0.470 
Hemoglobin fetal 
subunit beta  HBBF_BOVIN 16 kDa 61.7 55.9 42.4 26.5 52.7 56.0 20.0 51.7 1.0 0.899 61.6 33.4 60.0 39.0 1.0 0.864 
Filamin-A  FLNA_HUMAN 281 kDa 1.8 36.5 46.0 71.3 3.9 35.9 66.0 71.4 1.1 0.808 20.5 57.0 12.5 60.6 1.0 0.948 
Tubulin beta-5 chain  
TBB5_BOVIN 
(+1) 50 kDa 10.9 39.9 47.8 52.2 10.0 38.8 43.2 51.7 1.0 0.894 28.7 44.0 18.1 48.1 0.9 0.808 
Apolipoprotein A-I  APOA1_BOVIN 30 kDa 78.0 34.2 45.4 11.0 70.4 34.5 21.8 28.3 0.9 0.853 46.5 26.6 61.1 26.6 1.0 0.909 
Filamin-B  FLNB_HUMAN 278 kDa 1.8 25.1 37.5 64.0 2.8 24.4 68.2 54.2 1.2 0.797 6.8 51.6 4.5 38.2 0.8 0.710 
Complement C3  CO3_BOVIN 187 kDa 18.1 42.2 28.5 14.7 74.9 37.3 8.0 6.2 1.2 0.758 52.0 13.7 55.5 13.3 1.3 0.586 
Vitamin D-binding 
protein  VTDB_BOVIN 53 kDa 50.8 38.8 32.1 9.6 57.1 47.4 10.9 11.1 1.0 0.939 49.3 25.8 62.3 23.2 1.2 0.587 
Putative elongation 
factor 1-alpha-like 3  
EF1A3_HUMAN 
(+2) 50 kDa 32.6 35.4 47.8 30.9 12.2 41.6 37.4 51.7 1.0 0.923 38.3 35.7 29.4 35.7 0.9 0.678 
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Weight 1 2 3 4 1 2 3 4 Fold   P-value 1 2 3 4 Fold   P-value 
Glyceraldehyde-3-
phosphate 
dehydrogenase  G3P_HUMAN 36 kDa 16.3 25.1 33.9 37.5 8.9 18.7 29.7 53.0 1.0 0.954 16.4 28.9 14.7 43.2 0.9 0.777 
Fibronectin  FINC_BOVIN 272 kDa 23.6 26.3 10.9 25.0 22.7 24.4 27.2 34.5 1.3 0.241 21.9 21.3 11.3 36.5 1.1 0.842 
Hemoglobin subunit 
alpha  HBA_BOVIN 15 kDa 50.8 29.7 30.9 11.0 44.4 18.7 21.0 24.6 0.9 0.746 23.3 28.9 34.0 26.6 0.9 0.790 
Annexin A2  
ANXA2_HUMA
N 39 kDa 41.7 24.0 29.7 20.6 12.8 20.1 29.7 43.1 0.9 0.762 19.2 34.2 15.9 34.0 0.9 0.652 
Tubulin alpha-1C chain  TBA1C_CRIGR 50 kDa 5.4 18.3 40.6 22.8 10.0 14.4 38.1 34.5 1.1 0.816 13.7 34.9 12.5 33.2 1.1 0.855 
Elongation factor 2  
EF2_HUMAN 
(+1) 95 kDa 0.0 24.0 29.7 46.3 1.7 5.7 33.4 43.1 0.8 0.784 4.1 35.7 4.5 34.9 0.8 0.706 
Alpha-enolase  
ENOA_HUMAN 
(+1) 47 kDa 10.9 29.7 33.3 28.7 10.0 27.3 26.8 43.1 1.0 0.894 21.9 29.6 17.0 31.5 1.0 0.922 
Moesin  MOES_HUMAN 68 kDa 1.8 20.5 23.6 36.0 4.4 21.5 35.9 44.3 1.3 0.610 4.1 36.5 6.8 27.4 0.9 0.870 
Pyruvate kinase PKM  KPYM_HUMAN 58 kDa 3.6 18.3 31.5 35.3 5.0 7.2 34.1 45.6 1.0 0.951 8.2 30.4 4.5 29.9 0.8 0.708 
Kininogen-1  KNG1_BOVIN 69 kDa 25.4 32.0 18.2 7.4 35.5 31.6 5.4 6.2 0.9 0.917 38.3 15.9 46.4 14.1 1.4 0.444 
Heat shock protein HSP 
90-beta  
HS90B_HUMAN 
(+3) 83 kDa 0.0 4.6 13.9 46.3 0.6 2.9 33.7 56.7 1.4 0.685 5.5 22.8 6.8 43.2 1.2 0.815 
Alpha-1B-glycoprotein  A1BG_BOVIN 54 kDa 38.1 29.7 27.8 9.6 36.0 30.1 7.3 6.2 0.8 0.539 34.2 15.2 38.5 13.3 1.0 0.914 
Serpin A3-2  SPA32_BOVIN 46 kDa 30.8 18.3 20.6 3.7 42.7 21.5 5.8 7.4 1.1 0.924 27.4 11.4 29.4 10.0 1.1 0.880 
Peroxiredoxin-1  PRDX1_HUMAN 22 kDa 0.0 29.7 21.2 28.7 3.9 18.7 25.8 39.4 1.1 0.846 19.2 29.6 7.9 25.7 1.0 0.934 
Plasminogen  PLMN_BOVIN 91 kDa 9.1 24.0 16.3 5.9 37.7 28.7 2.5 2.5 1.3 0.704 32.8 8.4 36.2 8.3 1.6 0.420 
Basement membrane-
specific heparan sulfate 
proteoglycan core 
protein  PGBM_HUMAN 469 kDa 16.3 16.0 32.1 30.9 12.2 10.0 8.7 22.2 0.6 0.104 8.2 7.6 7.9 15.8 0.4 0.044 
Myosin-9  MYH9_HUMAN 227 kDa 0.0 4.6 11.5 48.5 0.0 1.4 44.6 48.0 1.5 0.684 0.0 25.1 2.3 23.2 0.8 0.797 
78 kDa glucose-
regulated protein  GRP78_HUMAN 72 kDa 14.5 5.7 20.6 17.6 8.9 4.3 22.9 38.2 1.3 0.659 12.3 37.2 10.2 31.5 1.6 0.332 
Alpha-1-acid 
glycoprotein  A1AG_BOVIN 23 kDa 32.6 8.0 24.2 1.5 42.7 15.8 8.7 2.5 1.1 0.944 23.3 12.9 37.4 8.3 1.2 0.702 
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Weight 1 2 3 4 1 2 3 4 Fold   P-value 1 2 3 4 Fold   P-value 
EGF-containing fibulin-
like extracellular matrix 
protein 1  
FBLN3_HUMAN 




AHNAK  AHNK_HUMAN 629 kDa 1.8 8.0 9.1 50.7 0.6 10.0 26.5 12.3 0.7 0.704 2.7 16.7 0.0 10.8 0.4 0.457 
Protein disulfide-
isomerase A3  
PDIA3_HUMAN 
(+1) 57 kDa 23.6 16.0 12.7 19.1 6.1 18.7 13.8 32.0 1.0 0.974 15.1 31.9 11.3 25.7 1.2 0.580 
Peptidyl-prolyl cis-trans 
isomerase A  PPIA_CHLAE 18 kDa 3.6 3.4 20.0 12.5 8.3 11.5 37.7 19.7 2.0 0.276 4.1 22.8 3.4 16.6 1.2 0.777 





(+3) 37 kDa 1.8 8.0 17.0 23.5 0.6 8.6 22.1 24.6 1.1 0.856 6.8 26.6 2.3 17.4 1.1 0.925 
L-lactate dehydrogenase 
A chain  LDHA_HUMAN 37 kDa 1.8 12.6 18.2 16.9 1.1 10.0 16.7 25.9 1.1 0.874 6.8 23.5 4.5 24.9 1.2 0.707 
Hemopexin  HEMO_BOVIN 52 kDa 5.4 11.4 13.9 4.4 36.6 14.4 2.2 1.2 1.5 0.609 16.4 3.8 29.4 5.0 1.6 0.492 
Alpha-actinin-1  ACTN1_HUMAN 103 kDa 0.0 5.7 27.2 20.6 3.3 4.3 35.6 22.2 1.2 0.778 0.0 19.7 0.0 14.9 0.6 0.584 
Cofilin-1  COF1_HUMAN 19 kDa 7.3 17.1 17.6 19.9 3.9 23.0 13.1 24.6 1.0 0.906 15.1 18.2 6.8 18.3 0.9 0.832 
14-3-3 protein epsilon  1433E_BOVIN 29 kDa 1.8 12.6 23.0 19.1 3.9 10.0 21.4 13.6 0.9 0.759 9.6 15.2 4.5 11.6 0.7 0.488 
L-lactate dehydrogenase 
B chain  LDHB_HUMAN 37 kDa 3.6 21.7 16.3 25.7 1.7 21.5 14.9 25.9 0.9 0.908 13.7 21.3 9.1 22.4 1.0 0.968 
Alpha-2-antiplasmin  A2AP_BOVIN 55 kDa 10.9 16.0 6.7 4.4 18.3 17.2 2.5 4.9 1.1 0.803 17.8 6.8 19.2 7.5 1.4 0.453 
Thrombospondin-1  TSP1_HUMAN 129 kDa 12.7 12.6 14.5 16.2 11.6 10.0 6.2 8.6 0.7 0.017 10.9 7.6 9.1 10.0 0.7 0.007 
Plasminogen activator 
inhibitor 1  PAI1_HUMAN 45 kDa 16.3 6.8 12.7 5.9 10.0 7.2 9.8 7.4 0.8 0.518 5.5 9.9 5.7 5.8 0.6 0.236 
Eukaryotic initiation 
factor 4A-I  
IF4A1_BOVIN 
(+1) 46 kDa 1.8 9.1 15.7 12.5 1.1 7.2 22.5 17.2 1.2 0.713 5.5 15.2 2.3 16.6 1.0 0.986 
Tropomyosin alpha-3 
chain  TPM3_RAT 29 kDa 9.1 10.3 10.9 14.0 2.2 17.2 17.1 14.8 1.2 0.663 13.7 12.9 7.9 12.5 1.1 0.693 
Heterogeneous nuclear 
ribonucleoprotein K  
HNRPK_HUMA
N (+2) 51 kDa 5.4 14.8 12.7 27.2 0.6 14.4 12.7 17.2 0.7 0.536 12.3 12.9 4.5 14.9 0.7 0.483 
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Weight 1 2 3 4 1 2 3 4 Fold   P-value 1 2 3 4 Fold   P-value 








(+1) 31 kDa 3.6 9.1 18.2 7.4 1.7 7.2 19.6 13.6 1.1 0.858 1.4 15.2 1.1 19.1 1.0 0.949 
Protein AMBP  AMBP_BOVIN 39 kDa 9.1 12.6 9.7 3.7 18.9 12.9 4.4 2.5 1.1 0.841 16.4 10.6 14.7 8.3 1.4 0.201 
Annexin A1  
ANXA1_HUMA
N 39 kDa 3.6 8.0 7.9 11.0 4.4 7.2 13.4 12.3 1.2 0.540 5.5 13.7 3.4 11.6 1.1 0.764 
A-kinase anchor protein 
12  AKA12_HUMAN 191 kDa 0.0 5.7 2.4 31.6 0.0 4.3 9.1 11.1 0.6 0.649 4.1 15.2 3.4 14.1 0.9 0.931 
Fructose-bisphosphate 
aldolase A  
ALDOA_HUMA
N 39 kDa 0.0 8.0 12.7 12.5 2.2 10.0 11.2 14.8 1.2 0.760 5.5 8.4 4.5 8.3 0.8 0.631 
Transketolase  TKT_HUMAN 68 kDa 0.0 3.4 13.3 14.7 0.0 4.3 14.9 16.0 1.1 0.867 1.4 12.9 2.3 14.9 1.0 0.999 
Clathrin heavy chain 1  
CLH1_HUMAN 
(+1) 192 kDa 0.0 3.4 8.5 18.4 0.0 2.9 18.1 14.8 1.2 0.825 2.7 10.6 0.0 14.1 0.9 0.897 
40S ribosomal protein S3  RS3_BOVIN (+1) 27 kDa 0.0 2.3 6.7 17.6 1.1 2.9 10.9 20.9 1.3 0.714 1.4 8.4 1.1 19.1 1.1 0.889 
Transgelin-2  
TAGL2_HUMAN 




(+1) 45 kDa 0.0 2.3 18.2 9.6 1.7 2.9 22.5 7.4 1.1 0.867 2.7 8.4 0.0 7.5 0.6 0.561 
Myosin light polypeptide 
6  
MYL6_BOVIN 
(+1) 17 kDa 0.0 6.8 8.5 18.4 1.1 4.3 11.2 23.4 1.2 0.808 4.1 11.4 2.3 11.6 0.9 0.820 
Inter-alpha-trypsin 
inhibitor heavy chain H4  ITIH4_BOVIN 102 kDa 3.6 4.6 9.1 0.0 25.0 1.4 1.8 0.0 1.6 0.688 4.1 3.8 11.3 0.8 1.2 0.819 
Thioredoxin domain-
containing protein 5  TXND5_HUMAN 48 kDa 14.5 5.7 12.7 4.4 6.1 8.6 7.3 8.6 0.8 0.556 5.5 13.7 5.7 12.5 1.0 0.995 
Antithrombin-III  ANT3_BOVIN 52 kDa 5.4 9.1 6.7 2.2 18.3 8.6 1.8 3.7 1.4 0.602 10.9 5.3 12.5 5.0 1.4 0.329 
Nucleoside diphosphate 
kinase B  
NDKB_MOUSE 
(+1) 17 kDa 0.0 9.1 9.1 14.0 0.6 8.6 11.2 11.1 1.0 0.966 8.2 12.9 5.7 7.5 1.1 0.882 
Talin-1  TLN1_HUMAN 270 kDa 0.0 4.6 5.4 20.6 0.0 8.6 17.4 12.3 1.3 0.750 2.7 6.1 1.1 10.8 0.7 0.643 
Calreticulin  
CALR_HUMAN 
(+1) 48 kDa 0.0 3.4 7.3 10.3 0.6 2.9 7.3 13.6 1.2 0.831 2.7 12.9 5.7 13.3 1.6 0.365 
Beta-2-glycoprotein 1  APOH_BOVIN 38 kDa 5.4 1.1 16.3 0.0 21.6 2.9 3.3 0.0 1.2 0.852 8.2 6.1 19.2 1.7 1.5 0.583 
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Weight 1 2 3 4 1 2 3 4 Fold  P-value 1 2 3 4 Fold   P-value 
Transitional endoplasmic 
reticulum ATPase  
TERA_HUMAN 
(+1) 89 kDa 0.0 2.3 12.1 8.8 0.0 0.0 21.0 13.6 1.5 0.653 0.0 14.4 0.0 9.1 1.0 0.985 
SPARC  SPRC_BOVIN 35 kDa 7.3 1.1 11.5 0.0 6.1 0.0 5.8 7.4 1.0 0.964 1.4 9.9 0.0 1.7 0.6 0.636 
Fascin  FSCN1_HUMAN 55 kDa 1.8 6.8 10.3 11.8 0.0 10.0 13.4 16.0 1.3 0.620 4.1 10.6 4.5 10.8 1.0 0.956 
40S ribosomal protein 
SA  
RSSA_CHICK 
(+2) 33 kDa 3.6 8.0 7.9 9.6 2.2 5.7 10.5 13.6 1.1 0.803 4.1 9.9 4.5 12.5 1.1 0.850 
Vinculin  VINC_HUMAN 124 kDa 0.0 6.8 6.1 13.2 0.0 4.3 15.6 12.3 1.2 0.747 1.4 9.1 0.0 10.0 0.8 0.716 
14-3-3 protein 
zeta/delta  1433Z_BOVIN 28 kDa 5.4 16.0 20.6 18.4 3.3 17.2 18.5 19.7 1.0 0.939 6.8 16.7 5.7 14.9 0.7 0.390 
Complement factor B  CFAB_BOVIN 85 kDa 5.4 11.4 6.7 3.7 18.3 11.5 1.8 2.5 1.3 0.708 10.9 3.8 12.5 5.8 1.2 0.602 
Peroxiredoxin-6  
PRDX6_HUMAN 
(+1) 25 kDa 1.8 4.6 6.7 9.6 0.6 4.3 8.3 11.1 1.1 0.886 4.1 9.1 1.1 9.1 1.0 0.934 
Myristoylated alanine-
rich C-kinase substrate  
MARCS_HUMA
N 32 kDa 9.1 12.6 6.1 8.8 1.1 11.5 4.0 9.9 0.7 0.410 8.2 9.9 5.7 7.5 0.9 0.443 
Chloride intracellular 
channel protein 1  CLIC1_HUMAN 27 kDa 1.8 8.0 10.9 9.6 0.0 5.7 11.2 14.8 1.0 0.925 5.5 9.1 2.3 8.3 0.8 0.634 
Connective tissue 
growth factor  CTGF_HUMAN 38 kDa 10.9 5.7 7.9 5.1 3.9 2.9 5.1 6.2 0.6 0.112 2.7 5.3 3.4 3.3 0.5 0.058 
Adenylyl cyclase-
associated protein 1  CAP1_HUMAN 52 kDa 0.0 4.6 6.1 7.4 0.0 4.3 11.2 9.9 1.4 0.569 4.1 9.1 2.3 6.6 1.2 0.652 
Inter-alpha-trypsin 
inhibitor heavy chain H2  ITIH2_MOUSE 106 kDa 7.3 8.0 7.3 0.7 11.6 7.2 2.2 1.2 1.0 0.935 12.3 6.8 13.6 2.5 1.5 0.373 
Peptidyl-prolyl cis-trans 
isomerase FKBP1A  
FKB1A_HUMAN 
(+2) 12 kDa 5.4 5.7 7.9 11.0 1.7 5.7 13.8 12.3 1.1 0.795 4.1 7.6 3.4 7.5 0.8 0.314 
Ubiquitin-40S ribosomal 
protein S27a  RS27A_BOVIN 18 kDa 3.6 5.7 6.1 5.9 0.6 5.7 7.3 9.9 1.1 0.808 2.7 9.1 1.1 4.2 0.8 0.602 
Serum albumin  ALBU_HUMAN 69 kDa 110.6 87.9 54.5 29.4 69.3 90.4 17.4 60.4 0.8 0.652 101.3 37.2 106.4 40.7 1.0 0.977 
Elongation factor 1-




(+1) 29 kDa 7.3 10.3 6.7 12.5 1.1 15.8 15.6 18.5 1.4 0.443 9.6 15.9 4.5 14.9 1.2 0.519 
10 kDa heat shock 
protein, mitochondrial  CH10_BOVIN 11 kDa 10.9 1.1 2.4 4.4 0.6 2.9 4.0 8.6 0.9 0.807 1.4 7.6 0.0 10.0 1.0 0.996 
Heterogeneous nuclear 
ribonucleoprotein A1  
ROA1_BOVIN 
(+1) 34 kDa 0.0 4.6 13.9 11.8 0.0 2.9 15.6 7.4 0.9 0.822 2.7 9.9 1.1 6.6 0.7 0.542 
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Weight 1 2 3 4 1 2 3 4 Fold   P-value 1 2 3 4 Fold   P-value 
Caldesmon  CALD1_HUMAN 93 kDa 0.0 3.4 5.4 14.0 0.0 1.4 8.0 8.6 0.8 0.758 2.7 10.6 3.4 9.1 1.1 0.839 
Transaldolase  TALDO_HUMAN 38 kDa 0.0 5.7 7.9 5.1 0.0 1.4 8.7 7.4 0.9 0.917 1.4 7.6 0.0 5.8 0.8 0.701 
Heat shock protein HSP 
90-alpha  
HS90A_HUMAN 
(+5) 85 kDa 0.0 0.0 8.5 35.3 0.0 0.0 25.0 43.1 1.6 0.667 0.0 15.9 6.8 33.2 1.3 0.792 
Protein-glutamine 
gamma-
glutamyltransferase 2  TGM2_HUMAN 77 kDa 0.0 4.6 6.1 11.8 0.0 2.9 5.1 4.9 0.6 0.425 4.1 6.1 3.4 5.0 0.8 0.725 
Spectrin alpha chain, 
non-erythrocytic 1  SPTN1_HUMAN 285 kDa 0.0 4.6 0.0 21.3 0.0 1.4 12.0 7.4 0.8 0.835 0.0 4.6 0.0 9.1 0.5 0.609 
Lactotransferrin  TRFL_HUMAN 78 kDa 0.0 0.0 0.0 0.0 0.0 15.8 52.6 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
40S ribosomal protein 
S20  
RS20_BOVIN 
(+2) 13 kDa 0.0 4.6 1.8 11.8 0.0 5.7 5.8 13.6 1.4 0.663 4.1 7.6 3.4 10.8 1.4 0.559 
Alpha-actinin-4  
ACTN4_HUMAN 
(+1) 105 kDa 0.0 6.8 27.2 22.8 0.0 4.3 33.7 24.6 1.1 0.893 0.0 22.8 0.0 14.1 0.6 0.581 
Pentraxin-related 
protein PTX3  PTX3_HUMAN 42 kDa 9.1 2.3 8.5 1.5 6.7 0.0 4.7 2.5 0.6 0.480 4.1 10.6 1.1 7.5 1.1 0.865 
Guanine nucleotide-
binding protein subunit 
beta-2-like 1  GBLP_BOVIN 35 kDa 3.6 2.3 6.7 5.9 1.7 2.9 12.7 7.4 1.3 0.599 2.7 6.1 1.1 10.8 1.1 0.820 
Apolipoprotein A-II  APOA2_BOVIN 11 kDa 10.9 3.4 3.0 2.9 7.8 4.3 3.3 6.2 1.1 0.895 4.1 4.6 2.3 4.2 0.7 0.558 
Filamin-C  FLNC_HUMAN 291 kDa 0.0 4.6 6.1 16.9 0.0 4.3 17.8 7.4 1.1 0.929 0.0 10.6 1.1 10.0 0.8 0.762 
Endothelial protein C 
receptor  EPCR_HUMAN 27 kDa 16.3 0.0 7.3 1.5 5.5 0.0 4.4 6.2 0.6 0.601 5.5 3.0 2.3 5.0 0.6 0.579 
Keratin, type II 
cytoskeletal 1  K2C1_HUMAN 66 kDa 0.0 0.0 1.8 1.5 2.2 4.3 13.1 2.5 6.7 0.163 0.0 0.0 1.1 1.7 0.8 0.852 
40S ribosomal protein 
S16  RS16_BOVIN 16 kDa 0.0 1.1 3.0 11.8 0.0 0.0 9.4 16.0 1.6 0.636 0.0 3.0 0.0 10.8 0.9 0.891 
Synaptic vesicle 
membrane protein VAT-
1 homolog  VAT1_HUMAN 42 kDa 1.8 3.4 4.8 7.4 0.0 2.9 10.5 7.4 1.2 0.763 1.4 6.1 0.0 5.0 0.7 0.527 
14-3-3 protein theta  1433T_BOVIN 28 kDa 3.6 12.6 18.8 16.9 2.8 14.4 15.6 16.0 0.9 0.872 10.9 15.2 4.5 12.5 0.8 0.613 
Adenosylhomocysteinas
e  SAHH_HUMAN 48 kDa 0.0 4.6 6.7 10.3 0.0 5.7 8.3 6.2 0.9 0.913 4.1 8.4 1.1 7.5 1.0 0.968 
Inter-alpha-trypsin 
inhibitor heavy chain H3  ITIH3_BOVIN 100 kDa 3.6 8.0 4.8 3.7 11.1 7.2 1.8 0.0 1.0 0.996 8.2 3.0 12.5 3.3 1.3 0.521 
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Weight 1 2 3 4 1 2 3 4 Fold   P-value 1 2 3 4 Fold   P-value 
Plastin-3  PLST_HUMAN 71 kDa 0.0 0.0 4.8 6.6 0.0 0.0 20.7 4.9 2.2 0.535 0.0 1.5 0.0 1.7 0.3 0.313 
Thymosin beta-12  
TYB12_LATJA 
(+5) 5 kDa 3.6 10.3 4.8 5.9 1.7 11.5 2.5 7.4 0.9 0.892 8.2 6.1 6.8 9.1 1.2 0.430 
Endoplasmin  ENPL_HUMAN 92 kDa 0.0 2.3 1.8 8.8 0.6 2.9 6.2 17.2 2.1 0.446 1.4 13.7 2.3 10.8 2.2 0.343 
Cytoplasmic dynein 1 
heavy chain 1  DYHC1_HUMAN 532 kDa 0.0 0.0 0.6 19.1 0.0 0.0 6.9 2.5 0.5 0.634 0.0 0.8 0.0 8.3 0.5 0.631 
Serum albumin  ALBU_EQUAS 69 kDa 70.7 57.1 30.3 21.3 41.0 66.0 13.1 29.6 0.8 0.659 78.0 23.5 57.7 28.2 1.0 0.910 
Gelsolin  GELS_BOVIN 81 kDa 1.8 5.7 3.6 2.2 11.1 7.2 1.5 1.2 1.6 0.499 2.7 3.0 9.1 3.3 1.4 0.525 
Keratin, type I 
cytoskeletal 10  K1C10_HUMAN 59 kDa 9.1 1.1 0.0 0.7 2.2 8.6 10.5 3.7 2.3 0.270 2.7 1.5 1.1 2.5 0.7 0.745 
Proliferation-associated 
protein 2G4  PA2G4_HUMAN 44 kDa 0.0 4.6 2.4 8.1 0.0 4.3 8.0 7.4 1.3 0.662 2.7 4.6 2.3 6.6 1.1 0.893 
Tubulin beta-6 chain  TBB6_HUMAN 50 kDa 0.0 16.0 18.2 17.6 0.0 12.9 22.5 27.1 1.2 0.731 6.8 22.0 4.5 14.1 0.9 0.861 
Heterogeneous nuclear 
ribonucleoprotein D-like  
HNRDL_HUMA
N 46 kDa 0.0 3.4 4.8 6.6 0.0 0.0 6.9 3.7 0.7 0.639 1.4 6.8 0.0 6.6 1.0 0.997 
WD repeat-containing 
protein 1  WDR1_HUMAN 66 kDa 0.0 1.1 9.1 3.7 0.0 0.0 14.1 6.2 1.5 0.700 0.0 4.6 0.0 3.3 0.6 0.548 
Cysteine and glycine-rich 
protein 1  
CSRP1_HUMAN 
(+2) 21 kDa 0.0 3.4 6.7 11.0 0.6 1.4 8.7 7.4 0.9 0.817 0.0 6.1 0.0 6.6 0.6 0.510 
T-complex protein 1 
subunit theta  TCPQ_HUMAN 60 kDa 0.0 4.6 4.8 11.0 0.0 4.3 8.3 7.4 1.0 0.974 2.7 6.1 2.3 9.1 1.0 0.984 
Microtubule-associated 
protein 4  MAP4_HUMAN 121 kDa 0.0 4.6 1.2 14.7 0.0 2.9 7.3 6.2 0.8 0.791 0.0 5.3 0.0 8.3 0.7 0.680 
Phosphoglycerate 
mutase 1  
PGAM1_HUMA
N (+1) 29 kDa 0.0 4.6 4.2 6.6 0.6 1.4 9.4 4.9 1.1 0.928 0.0 4.6 0.0 6.6 0.7 0.645 
Beta-actin-like protein 2  ACTBL_MOUSE 42 kDa 23.6 24.0 59.3 25.7 17.7 0.0 48.6 55.4 0.9 0.870 19.2 41.8 15.9 34.0 0.8 0.630 
40S ribosomal protein 
S12  
RS12_BOVIN 
(+3) 15 kDa 0.0 3.4 1.8 5.1 0.0 0.0 5.8 9.9 1.5 0.643 0.0 6.1 0.0 8.3 1.4 0.696 
Insulin-like growth 
factor-binding protein 7  IBP7_HUMAN 29 kDa 7.3 3.4 3.6 3.7 1.7 5.7 4.7 4.9 0.9 0.861 1.4 7.6 4.5 5.0 1.0 0.941 
Complement C4 
(Fragments)  CO4_BOVIN 102 kDa 3.6 3.4 3.0 1.5 13.3 8.6 0.7 2.5 2.2 0.327 4.1 3.0 5.7 1.7 1.3 0.490 
Brain acid soluble 
protein 1  BASP1_HUMAN 23 kDa 5.4 5.7 4.2 6.6 1.1 5.7 2.5 6.2 0.7 0.291 5.5 6.8 2.3 7.5 1.0 0.994 
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Weight 1 2 3 4 1 2 3 4 Fold   P-value 1 2 3 4 Fold   P-value 
Purine nucleoside 
phosphorylase  PNPH_HUMAN 32 kDa 0.0 0.0 6.7 1.5 1.1 0.0 15.6 2.5 2.4 0.524 0.0 2.3 0.0 2.5 0.6 0.651 
Trypsin  TRYP_PIG 24 kDa 14.5 6.8 3.6 1.5 3.3 8.6 1.5 3.7 0.6 0.504 8.2 1.5 6.8 2.5 0.7 0.597 
Collagen alpha-1(I) chain  CO1A1_BOVIN 139 kDa 5.4 6.8 0.6 2.9 1.7 12.9 4.7 0.0 1.2 0.798 4.1 4.6 4.5 5.0 1.1 0.702 
Aminopeptidase N  AMPN_HUMAN 110 kDa 3.6 2.3 3.6 6.6 0.0 2.9 7.3 2.5 0.8 0.635 1.4 3.8 1.1 5.0 0.7 0.388 
60S ribosomal protein L7  RL7_HUMAN 29 kDa 0.0 0.0 0.0 11.0 0.0 0.0 2.9 8.6 1.0 0.972 0.0 0.8 0.0 9.1 0.9 0.939 
Heterogeneous nuclear 
ribonucleoprotein H  
HNRH1_HUMA
N (+1) 49 kDa 0.0 6.8 4.8 9.6 0.0 1.4 6.2 4.9 0.6 0.417 2.7 4.6 3.4 6.6 0.8 0.678 
Peptidyl-prolyl cis-trans 
isomerase B  PPIB_HUMAN 24 kDa 1.8 0.0 4.2 2.9 2.2 0.0 6.2 6.2 1.6 0.470 0.0 8.4 1.1 6.6 1.8 0.468 
Serpin A3-7  SPA37_BOVIN 47 kDa 14.5 8.0 9.1 0.0 13.9 11.5 3.3 3.7 1.0 0.965 13.7 6.8 13.6 5.8 1.3 0.593 





(+1) 36 kDa 3.6 3.4 0.6 5.9 0.0 4.3 2.5 4.9 0.9 0.785 1.4 3.0 2.3 4.2 0.8 0.607 
Cathepsin B  CATB_HUMAN 38 kDa 3.6 4.6 4.2 6.6 1.1 4.3 3.6 3.7 0.7 0.152 1.4 8.4 1.1 5.0 0.8 0.684 
GTP-binding nuclear 
protein Ran  
RAN_BOVIN 
(+6) 24 kDa 0.0 4.6 6.1 6.6 0.0 1.4 5.1 9.9 0.9 0.938 0.0 5.3 0.0 6.6 0.7 0.588 
Rab GDP dissociation 
inhibitor beta  GDIB_HUMAN 51 kDa 0.0 1.1 3.0 10.3 0.0 0.0 9.1 1.2 0.7 0.755 1.4 3.8 0.0 1.7 0.5 0.481 




(+7) 16 kDa 3.6 4.6 4.8 2.9 1.1 4.3 6.9 7.4 1.2 0.574 2.7 3.8 2.3 4.2 0.8 0.269 
Splicing factor, proline- 
and glutamine-rich  SFPQ_HUMAN 76 kDa 3.6 2.3 1.8 4.4 0.6 2.9 2.5 3.7 0.8 0.515 2.7 6.1 0.0 5.8 1.2 0.710 
Polyadenylate-binding 
protein 1  PABP1_RAT 71 kDa 0.0 1.1 4.8 3.7 0.0 1.4 10.5 2.5 1.5 0.671 0.0 6.8 0.0 3.3 1.1 0.952 
40S ribosomal protein 
S21  RS21_BOVIN 9 kDa 0.0 3.4 3.0 7.4 0.0 1.4 4.4 7.4 1.0 0.946 4.1 4.6 2.3 3.3 1.0 0.948 
Plasminogen activator 
inhibitor 1 RNA-binding 
protein  PAIRB_HUMAN 45 kDa 0.0 1.1 1.8 10.3 0.0 0.0 3.6 6.2 0.7 0.769 0.0 4.6 1.1 5.8 0.9 0.879 
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Weight 1 2 3 4 1 2 3 4 Fold   P-value 1 2 3 4 Fold   P-value 
ATP-citrate synthase  ACLY_HUMAN 121 kDa 0.0 3.4 3.0 9.6 0.0 0.0 6.5 2.5 0.6 0.515 0.0 5.3 1.1 5.0 0.7 0.654 
Staphylococcal nuclease 
domain-containing 
protein 1  SND1_HUMAN 102 kDa 0.0 2.3 2.4 7.4 0.0 0.0 8.3 6.2 1.2 0.825 0.0 3.8 0.0 7.5 0.9 0.936 
Rho GDP-dissociation 
inhibitor 2  GDIR2_HUMAN 23 kDa 1.8 3.4 2.4 4.4 0.0 5.7 3.3 3.7 1.1 0.910 2.7 3.8 1.1 4.2 1.0 0.945 




N (+2) 36 kDa 3.6 0.0 1.8 0.7 1.1 1.4 3.3 2.5 1.3 0.597 0.0 6.1 0.0 3.3 1.5 0.651 
Glutathione S-
transferase omega-1  GSTO1_HUMAN 28 kDa 0.0 3.4 4.2 5.9 0.0 2.9 7.3 3.7 1.0 0.973 0.0 4.6 0.0 2.5 0.5 0.365 
40S ribosomal protein S2  
RS2_HUMAN 
(+2) 31 kDa 0.0 2.3 2.4 8.8 0.6 2.9 5.4 12.3 1.6 0.570 0.0 3.0 0.0 10.8 1.0 0.982 
6-phosphogluconate 
dehydrogenase, 
decarboxylating  6PGD_HUMAN 53 kDa 0.0 2.3 5.4 5.9 0.0 0.0 7.3 4.9 0.9 0.881 0.0 5.3 0.0 4.2 0.7 0.616 
Eukaryotic translation 
initiation factor 5A-1  
IF5A1_BOVIN 
(+1) 17 kDa 0.0 1.1 8.5 5.1 1.1 0.0 8.7 3.7 0.9 0.913 0.0 5.3 0.0 3.3 0.6 0.540 
Prelamin-A/C  LMNA_HUMAN 74 kDa 0.0 0.0 1.8 8.1 0.0 1.4 6.9 13.6 2.2 0.446 0.0 9.1 0.0 8.3 1.8 0.576 
T-complex protein 1 
subunit gamma  
TCPG_HUMAN 
(+1) 61 kDa 0.0 1.1 3.0 9.6 0.0 0.0 7.6 7.4 1.1 0.920 0.0 4.6 0.0 5.8 0.8 0.761 
Glutathione S-
transferase P  GSTP1_HUMAN 23 kDa 0.0 1.1 8.5 5.1 1.1 2.9 7.3 4.9 1.1 0.887 1.4 5.3 0.0 4.2 0.7 0.686 
Plectin  PLEC_HUMAN 532 kDa 0.0 2.3 0.0 9.6 0.0 1.4 4.0 8.6 1.2 0.858 0.0 0.8 0.0 6.6 0.6 0.705 
40S ribosomal protein 
S18  RS18_BOVIN 18 kDa 0.0 2.3 2.4 5.1 0.6 1.4 3.6 6.2 1.2 0.779 1.4 4.6 1.1 7.5 1.5 0.549 
T-complex protein 1 
subunit alpha  
TCPA_HUMAN 
(+1) 60 kDa 0.0 0.0 1.2 9.6 0.0 0.0 4.0 4.9 0.8 0.868 0.0 3.0 0.0 4.2 0.7 0.741 
40S ribosomal protein S8  RS8_BOVIN 24 kDa 0.0 0.0 1.8 7.4 0.0 0.0 7.3 11.1 2.0 0.513 0.0 0.0 0.0 10.0 1.1 0.950 
Pantetheinase  VNN1_BOVIN 57 kDa 1.8 4.6 3.0 1.5 6.7 5.7 0.4 2.5 1.4 0.536 6.8 1.5 6.8 2.5 1.6 0.336 
High mobility group 
protein HMG-I/HMG-Y  
HMGA1_CANFA 
(+2) 12 kDa 0.0 2.3 1.2 11.0 0.0 0.0 2.2 7.4 0.7 0.701 2.7 4.6 0.0 10.8 1.2 0.802 
Protein disulfide-
isomerase A4 PDIA4_HUMAN 73 kDa 0.0 0.0 0.6 3.7 0.0 0.0 3.3 6.2 2.2 0.490 0.0 9.1 0.0 5.0 3.3 0.360 
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(+1) 46 kDa 21.8 16.0 17.0 0.0 42.1 17.2 4.0 0.0 1.2 0.847 26.0 9.1 24.9 7.5 1.2 0.657 
40S ribosomal protein 
S4, X isoform 
RS4X_CHLAE 
(+4) 30 kDa 0.0 0.0 1.2 9.6 0.0 0.0 3.3 12.3 1.4 0.757 0.0 0.8 0.0 6.6 0.7 0.776 
Putative 40S ribosomal 
protein S26-like 1 
RS26L_HUMAN 
(+2) 13 kDa 0.0 0.0 0.0 9.6 0.0 0.0 1.8 6.2 0.8 0.893 0.0 0.0 1.1 7.5 0.9 0.939 
T-complex protein 1 
subunit eta 
TCPH_HUMAN 
(+1) 59 kDa 0.0 0.0 2.4 6.6 0.0 0.0 6.5 1.2 0.9 0.890 0.0 3.0 0.0 3.3 0.7 0.727 
Heat shock protein 105 
kDa  
HS105_HUMAN 
(+1) 97 kDa 0.0 3.4 1.8 5.9 0.0 1.4 8.0 3.7 1.2 0.825 1.4 5.3 2.3 4.2 1.2 0.760 
Factor XIIa inhibitor  F12AI_BOVIN 52 kDa 0.0 4.6 1.8 0.0 13.3 4.3 0.0 0.0 2.8 0.448 4.1 0.0 5.7 0.0 1.5 0.657 
40S ribosomal protein 
S3a  
RS3A_BOVIN 
(+4) 30 kDa 0.0 0.0 1.2 5.1 0.0 0.0 5.1 8.6 2.2 0.486 0.0 2.3 0.0 6.6 1.4 0.759 
Tubulin beta-4B chain  TBB4B_BOVIN 50 kDa 10.9 39.9 38.1 51.5 8.9 37.3 37.4 48.0 0.9 0.860 27.4 38.0 18.1 42.3 0.9 0.734 
RNA-binding protein FUS  FUS_BOVIN 52 kDa 0.0 1.1 1.8 5.1 0.0 2.9 2.9 4.9 1.3 0.680 1.4 3.0 2.3 5.0 1.4 0.538 
Heat shock protein beta-
1  HSPB1_HUMAN 23 kDa 0.0 2.3 4.2 5.1 0.6 2.9 5.8 3.7 1.1 0.848 1.4 5.3 0.0 5.0 1.0 1.000 
60S ribosomal protein 
L12  
RL12_BOVIN 
(+2) 18 kDa 0.0 1.1 1.2 11.0 0.0 0.0 4.0 11.1 1.1 0.912 0.0 0.8 0.0 8.3 0.7 0.753 
Stress-induced-
phosphoprotein 1  STIP1_HUMAN 63 kDa 0.0 1.1 2.4 7.4 0.0 0.0 3.3 3.7 0.6 0.626 0.0 1.5 0.0 4.2 0.5 0.519 
Fibronectin  FINC_HUMAN 263 kDa 10.9 9.1 9.7 14.7 9.4 5.7 16.3 16.0 1.1 0.800 6.8 12.9 6.8 17.4 1.0 0.972 
26S proteasome non-
ATPase regulatory 
subunit 2  
PSMD2_HUMA
N 100 kDa 0.0 1.1 0.0 8.1 0.6 2.9 4.7 3.7 1.3 0.775 4.1 4.6 4.5 5.8 2.1 0.300 
T-complex protein 1 
subunit delta  
TCPD_HUMAN 
(+2) 58 kDa 0.0 2.3 2.4 7.4 0.0 0.0 3.3 7.4 0.9 0.886 0.0 3.0 0.0 3.3 0.5 0.466 
40S ribosomal protein 
S13  
RS13_BOVIN 
(+1) 17 kDa 0.0 1.1 1.8 10.3 0.0 0.0 4.0 6.2 0.8 0.793 0.0 0.8 0.0 5.8 0.5 0.570 
Ubiquitin-like modifier-
activating enzyme 1  UBA1_HUMAN 118 kDa 0.0 0.0 3.0 5.9 0.0 1.4 9.8 2.5 1.5 0.664 0.0 2.3 0.0 0.8 0.3 0.393 
CD59 glycoprotein  CD59_HUMAN 14 kDa 3.6 2.3 1.2 2.9 0.6 2.9 1.5 2.5 0.7 0.388 1.4 2.3 0.0 2.5 0.6 0.247 
60S ribosomal protein 
L30  
RL30_BOVIN 
(+1) 13 kDa 0.0 5.7 2.4 6.6 0.6 1.4 5.1 4.9 0.8 0.734 1.4 3.0 0.0 5.8 0.7 0.587 
60S ribosomal protein L6  RL6_HUMAN 33 kDa 0.0 0.0 0.0 8.8 0.0 0.0 2.5 8.6 1.3 0.852 0.0 1.5 0.0 10.0 1.3 0.845 
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Weight 1 2 3 4 1 2 3 4 Fold  P-value 1 2 3 4 Fold   P-value 
60S ribosomal protein L5  RL5_HUMAN 34 kDa 0.0 0.0 2.4 9.6 0.0 0.0 4.4 4.9 0.8 0.808 0.0 2.3 0.0 5.0 0.6 0.665 
60S ribosomal protein 
L13  RL13_HUMAN 24 kDa 0.0 0.0 0.0 8.1 0.0 0.0 3.6 7.4 1.4 0.794 0.0 0.0 0.0 5.0 0.6 0.757 
Adiponectin  ADIPO_BOVIN 26 kDa 0.0 1.1 1.2 2.2 5.0 2.9 0.7 0.0 1.9 0.454 5.5 1.5 3.4 2.5 2.8 0.087 
Eukaryotic translation 
initiation factor 2 
subunit 1  IF2A_HUMAN 36 kDa 0.0 1.1 0.6 8.1 0.6 1.4 3.3 2.5 0.8 0.804 1.4 5.3 1.1 3.3 1.1 0.885 
Malate dehydrogenase, 
cytoplasmic  MDHC_HUMAN 36 kDa 0.0 3.4 2.4 8.1 0.0 2.9 4.4 1.2 0.6 0.514 4.1 3.8 2.3 3.3 1.0 0.953 
40S ribosomal protein 
S14  
RS14_CRIGR 
(+1) 16 kDa 0.0 2.3 1.8 2.9 0.0 1.4 3.6 3.7 1.2 0.711 2.7 3.8 0.0 3.3 1.4 0.533 
40S ribosomal protein 
S25  RS25_BOVIN 14 kDa 0.0 2.3 1.2 5.1 1.1 0.0 2.9 7.4 1.3 0.739 2.7 3.0 1.1 5.0 1.4 0.573 
Ras GTPase-activating-
like protein IQGAP1  IQGA1_HUMAN 189 kDa 0.0 1.1 0.0 2.9 0.0 2.9 8.7 1.2 3.1 0.350 0.0 0.8 0.0 0.8 0.4 0.446 
Zyxin  ZYX_HUMAN 61 kDa 0.0 2.3 1.2 6.6 0.0 2.9 5.4 6.2 1.4 0.607 1.4 3.0 0.0 4.2 0.8 0.829 
60S ribosomal protein 
L18  
RL18_HUMAN 
(+2) 22 kDa 0.0 0.0 0.0 6.6 0.0 0.0 4.4 9.9 2.1 0.535 0.0 0.0 0.0 10.8 1.6 0.755 
Histone H2A type 1-B/E  
H2A1B_HUMAN 
(+22) 14 kDa 1.8 1.1 1.8 0.7 1.1 0.0 1.1 2.5 0.8 0.728 1.4 2.3 0.0 0.8 0.8 0.659 
14-3-3 protein gamma  
1433G_HUMAN 
(+2) 28 kDa 0.0 9.1 15.1 13.2 0.0 10.0 12.7 9.9 0.9 0.789 8.2 9.9 4.5 9.1 0.8 0.709 
Macrophage migration 
inhibitory factor  MIF_HUMAN 12 kDa 0.0 2.3 3.6 2.9 1.1 2.9 3.3 4.9 1.4 0.484 0.0 6.8 1.1 4.2 1.4 0.660 
60S ribosomal protein 
L27a  RL27A_HUMAN 17 kDa 0.0 0.0 0.6 5.9 0.0 0.0 3.6 9.9 2.1 0.550 0.0 0.8 0.0 5.8 1.0 0.992 
Glucose-6-phosphate 
isomerase  G6PI_HUMAN 63 kDa 0.0 2.3 3.0 6.6 0.0 5.7 5.4 1.2 1.0 0.953 0.0 3.0 0.0 2.5 0.5 0.362 
Nestin  NEST_HUMAN 177 kDa 0.0 1.1 0.0 11.8 0.0 0.0 2.9 6.2 0.7 0.778 0.0 2.3 0.0 5.8 0.6 0.722 
Heat shock 70 kDa 
protein 4  
HSP74_HUMAN 
(+1) 94 kDa 0.0 0.0 3.6 5.1 0.0 0.0 8.7 0.0 1.0 0.995 0.0 2.3 0.0 2.5 0.5 0.530 
Protein DJ-1  PARK7_HUMAN 20 kDa 0.0 0.0 1.2 5.9 0.0 0.0 5.1 3.7 1.2 0.833 0.0 0.8 0.0 1.7 0.3 0.473 
Thioredoxin  
THIO_HUMAN 
(+1) 12 kDa 1.8 3.4 2.4 2.2 0.6 2.9 3.3 3.7 1.1 0.875 4.1 2.3 0.0 2.5 0.9 0.799 
Histone H4 type VIII  H48_CHICK (+9) 11 kDa 1.8 4.6 0.6 2.2 0.0 4.3 2.2 1.2 0.8 0.775 0.0 3.0 0.0 2.5 0.6 0.459 
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Weight 1 2 3 4 1 2 3 4 Fold  P-value 1 2 3 4 Fold   P-value 
Septin-11  
SEP11_HUMAN 
(+1) 49 kDa 0.0 2.3 1.2 6.6 0.0 1.4 1.5 2.5 0.5 0.482 0.0 5.3 1.1 3.3 1.0 0.965 
Ubiquitin carboxyl-
terminal hydrolase 
isozyme L1  UCHL1_HUMAN 25 kDa 0.0 2.3 1.8 5.1 0.0 2.9 3.6 2.5 1.0 0.959 1.4 1.5 1.1 4.2 0.9 0.841 
F-actin-capping protein 
subunit alpha-1  CAZA1_HUMAN 33 kDa 0.0 2.3 2.4 2.9 0.0 4.3 4.0 3.7 1.6 0.406 0.0 3.0 1.1 4.2 1.1 0.887 
Prosaposin  SAP_HUMAN 58 kDa 0.0 0.0 2.4 1.5 0.0 0.0 4.4 3.7 2.1 0.468 0.0 5.3 0.0 1.7 1.8 0.606 
Ras-related C3 
botulinum toxin 
substrate 1  RAC1_BOVIN 21 kDa 0.0 2.3 1.8 2.9 0.0 0.0 4.7 6.2 1.5 0.607 0.0 4.6 0.0 2.5 1.0 0.999 
Kininogen-2  KNG2_BOVIN 69 kDa 23.6 26.3 17.6 0.0 27.7 20.1 5.1 0.0 0.8 0.693 27.4 12.9 32.8 0.0 1.1 0.885 
60S ribosomal protein 
L10a  
RL10A_BOVIN 
(+1) 25 kDa 0.0 1.1 1.2 2.2 0.6 0.0 2.5 3.7 1.5 0.593 0.0 1.5 1.1 3.3 1.3 0.685 
Proteasome subunit 
beta type-1  PSB1_HUMAN 26 kDa 0.0 2.3 1.8 5.1 0.0 2.9 2.9 2.5 0.9 0.850 2.7 3.0 0.0 5.0 1.2 0.807 
Actin, muscle  ACTM_APLCA 42 kDa 0.0 59.3 55.1 59.6 21.6 63.2 50.4 87.5 1.3 0.565 0.0 69.1 40.8 65.6 1.0 0.987 
60 kDa heat shock 
protein, mitochondrial  CH60_HUMAN 61 kDa 0.0 0.0 1.2 4.4 0.0 0.0 1.1 2.5 0.6 0.684 0.0 8.4 0.0 10.8 3.4 0.325 
Tropomyosin beta chain  
TPM2_HUMAN 
(+1) 33 kDa 5.4 5.7 5.4 8.1 1.1 5.7 12.3 12.3 1.3 0.583 6.8 12.9 2.3 10.0 1.3 0.490 
F-actin-capping protein 
subunit beta  
CAPZB_HUMAN 
(+4) 31 kDa 0.0 1.1 2.4 5.1 0.0 0.0 4.7 2.5 0.8 0.817 0.0 5.3 0.0 2.5 0.9 0.898 
Serum albumin  
ALBU_MACFA 
(+1) 69 kDa 134.2 119.8 67.8 0.0 97.0 127.8 0.0 0.0 0.7 0.608 156.0 49.4 155.1 56.4 1.3 0.596 
Tyrosine--tRNA ligase, 
cytoplasmic  SYYC_HUMAN 59 kDa 0.0 3.4 1.8 4.4 0.0 2.9 1.8 3.7 0.9 0.808 1.4 3.0 0.0 4.2 0.9 0.844 
60S ribosomal protein 
L27  
RL27_BOVIN 
(+1) 16 kDa 0.0 0.0 0.0 5.1 0.0 0.0 3.3 6.2 1.8 0.606 0.0 0.0 0.0 5.8 1.1 0.935 
Apolipoprotein E  APOE_BOVIN 36 kDa 3.6 3.4 0.6 2.2 3.3 4.3 0.0 1.2 0.9 0.843 1.4 1.5 1.1 3.3 0.7 0.492 
T-complex protein 1 
subunit beta  TCPB_HUMAN 57 kDa 0.0 0.0 1.2 5.9 0.0 1.4 2.9 6.2 1.5 0.674 0.0 3.8 1.1 4.2 1.3 0.784 
Glucose-6-phosphate 1-
dehydrogenase  G6PD_HUMAN 59 kDa 0.0 2.3 1.2 2.9 0.0 0.0 4.7 0.0 0.7 0.763 0.0 3.0 0.0 4.2 1.1 0.885 
Spectrin beta chain, 
non-erythrocytic 1  SPTB2_HUMAN 275 kDa 0.0 0.0 0.0 7.4 0.0 0.0 2.9 1.2 0.6 0.704 0.0 1.5 0.0 4.2 0.8 0.849 
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Weight 1 2 3 4 1 2 3 4 Fold  P-value 1 2 3 4 Fold   P-value 
Follistatin-related 
protein 1  
FSTL1_HUMAN 
(+3) 35 kDa 1.8 1.1 0.6 1.5 0.0 2.9 2.9 1.2 1.4 0.547 0.0 3.0 0.0 0.0 0.6 0.571 
72 kDa type IV 
collagenase  MMP2_HUMAN 74 kDa 1.8 2.3 1.2 1.5 0.0 1.4 0.7 1.2 0.5 0.080 0.0 3.0 2.3 0.8 0.9 0.835 
Prothrombin  THRB_BOVIN 71 kDa 0.0 1.1 1.8 0.7 10.0 0.0 0.7 0.0 2.9 0.527 4.1 0.0 2.3 0.0 1.7 0.564 
PDZ and LIM domain 
protein 5  PDLI5_HUMAN 64 kDa 0.0 0.0 1.2 9.6 0.0 0.0 2.9 1.2 0.4 0.533 0.0 0.0 0.0 4.2 0.4 0.547 
Proteasome subunit 
alpha type-1  
PSA1_HUMAN 
(+2) 30 kDa 0.0 2.3 1.8 2.9 0.0 1.4 2.9 2.5 1.0 0.949 0.0 2.3 1.1 3.3 1.0 0.938 
Rho GDP-dissociation 
inhibitor 1  GDIR1_HUMAN 23 kDa 0.0 1.1 3.0 2.2 0.6 1.4 6.2 6.2 2.2 0.291 0.0 3.0 1.1 3.3 1.2 0.795 
Four and a half LIM 
domains protein 2  FHL2_HUMAN 32 kDa 0.0 2.3 1.2 5.9 0.0 1.4 3.6 2.5 0.8 0.768 1.4 2.3 1.1 1.7 0.7 0.607 
Far upstream element-
binding protein 2  FUBP2_HUMAN 73 kDa 0.0 0.0 0.0 6.6 0.0 0.0 1.1 2.5 0.5 0.686 1.4 3.8 0.0 2.5 1.2 0.894 
Fatty acid synthase  FAS_HUMAN 273 kDa 0.0 0.0 1.2 8.1 0.0 0.0 2.9 3.7 0.7 0.770 0.0 3.0 0.0 2.5 0.6 0.677 
Zinc finger protein 185  ZN185_HUMAN 74 kDa 0.0 1.1 0.0 3.7 0.0 0.0 3.3 3.7 1.4 0.701 0.0 0.8 1.1 1.7 0.7 0.752 
Sulfhydryl oxidase 1  
QSOX1_HUMA
N 83 kDa 1.8 1.1 1.2 1.5 0.0 2.9 1.5 1.2 1.0 0.975 0.0 3.0 1.1 2.5 1.2 0.737 
60S ribosomal protein 
L18a  
RL18A_BOVIN 
(+1) 21 kDa 0.0 3.4 0.0 6.6 0.0 0.0 2.2 3.7 0.6 0.594 1.4 1.5 1.1 4.2 0.8 0.801 
Proteasome subunit 
beta type-5  
PSB5_HUMAN 




(+1) 52 kDa 0.0 0.0 1.2 0.7 0.0 0.0 1.8 1.2 1.6 0.634 0.0 3.8 0.0 2.5 3.2 0.342 
Cysteine-rich protein 2  
CRIP2_HUMAN 
(+1) 22 kDa 0.0 2.3 1.2 3.7 0.0 4.3 4.0 2.5 1.5 0.503 1.4 1.5 1.1 2.5 0.9 0.854 
Nuclear migration 




(+1) 28 kDa 0.0 5.7 14.5 9.6 0.0 7.2 12.3 7.4 0.9 0.862 6.8 9.1 3.4 6.6 0.9 0.787 
Proteasome subunit 
alpha type-4  
PSA4_BOVIN 
(+1) 29 kDa 0.0 0.0 3.0 2.9 0.0 0.0 4.0 4.9 1.5 0.656 0.0 2.3 0.0 1.7 0.7 0.645 
Myosin regulatory light 
chain 12A  
ML12A_HUMA
N (+6) 20 kDa 0.0 0.0 1.8 6.6 0.0 0.0 5.4 11.1 2.0 0.540 0.0 3.8 0.0 5.0 1.0 0.968 
Actin-1  ACT1_ECHGR 42 kDa 63.5 0.0 46.6 48.5 21.1 54.5 38.8 0.0 0.7 0.564 49.3 61.5 36.2 52.3 1.3 0.529 
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Weight 1 2 3 4 1 2 3 4 Fold   P-value 1 2 3 4 Fold   P-value 
Spliceosome RNA 
helicase DDX39B  
DX39B_HUMAN 
(+4) 49 kDa 0.0 0.0 1.2 3.7 0.0 4.3 6.5 1.2 2.5 0.345 0.0 3.8 0.0 1.7 1.1 0.913 
X-ray repair cross-
complementing protein 
6  XRCC6_HUMAN 70 kDa 0.0 0.0 1.8 3.7 0.0 0.0 5.1 0.0 0.9 0.949 0.0 2.3 0.0 1.7 0.7 0.727 
Proteasome subunit 
beta type-6  PSB6_HUMAN 25 kDa 0.0 1.1 1.2 2.9 0.0 4.3 1.5 3.7 1.8 0.415 2.7 3.0 2.3 3.3 2.1 0.082 
14-3-3 protein eta  1433F_HUMAN 28 kDa 0.0 5.7 13.9 10.3 0.0 10.0 12.0 8.6 1.0 0.966 5.5 9.9 3.4 6.6 0.8 0.747 
Inter-alpha-trypsin 
inhibitor heavy chain H1  ITIH1_BOVIN 101 kDa 0.0 3.4 1.2 1.5 4.4 2.9 0.0 0.0 1.2 0.828 4.1 0.0 3.4 0.8 1.4 0.665 
Far upstream element-
binding protein 1  FUBP1_HUMAN 68 kDa 0.0 2.3 0.0 8.1 0.0 1.4 2.2 2.5 0.6 0.621 0.0 2.3 1.1 2.5 0.6 0.609 
Ubiquitin-conjugating 
enzyme E2 variant 1  
UB2V1_BOVIN 
(+1) 16 kDa 0.0 1.1 1.8 2.9 0.0 0.0 2.9 0.0 0.5 0.462 0.0 1.5 0.0 1.7 0.5 0.413 
Actin-related protein 2/3 
complex subunit 1B  ARC1B_HUMAN 41 kDa 0.0 2.3 1.2 4.4 0.6 1.4 4.4 1.2 1.0 0.950 1.4 1.5 1.1 1.7 0.7 0.596 
Retinol-binding protein 
4  RET4_BOVIN 21 kDa 5.4 2.3 1.2 0.0 5.0 4.3 0.0 0.0 1.0 0.961 6.8 0.0 4.5 0.0 1.3 0.779 
Cytoplasmic dynein 1 
intermediate chain 2  DC1I2_HUMAN 71 kDa 0.0 0.0 1.2 5.9 0.0 0.0 2.2 2.5 0.7 0.712 0.0 4.6 1.1 4.2 1.4 0.716 
Annexin A5  
ANXA5_HUMA
N 36 kDa 0.0 0.0 3.0 1.5 0.6 0.0 2.5 0.0 0.7 0.723 0.0 2.3 0.0 3.3 1.2 0.812 
Poly(rC)-binding protein 
1  PCBP1_BOVIN 37 kDa 0.0 2.3 1.8 2.9 0.0 1.4 2.2 2.5 0.9 0.783 0.0 1.5 0.0 2.5 0.6 0.422 
Fibrinogen alpha chain  FIBA_BOVIN 67 kDa 0.0 1.1 0.6 0.0 6.7 1.4 0.7 0.0 5.0 0.329 0.0 0.0 3.4 0.0 1.9 0.670 
Chaperone protein DnaK  DNAK_MYCPU 66 kDa 0.0 0.0 3.6 2.2 0.6 0.0 4.4 3.7 1.5 0.643 0.0 1.5 1.1 2.5 0.9 0.873 
Neuronal cell adhesion 
molecule  
NRCAM_HUMA
N 144 kDa 7.3 1.1 0.0 5.1 0.0 0.0 0.7 0.0 0.1 0.155 2.7 0.0 0.0 0.8 0.3 0.244 
EF-hand domain-





(+1) 47 kDa 1.8 0.0 2.4 0.0 0.0 0.0 3.6 2.5 1.4 0.691 0.0 6.1 0.0 5.0 2.6 0.381 
DNA-(apurinic or 
apyrimidinic site) lyase  APEX1_PANPA 36 kDa 0.0 1.1 3.6 4.4 0.0 0.0 1.5 1.2 0.3 0.219 0.0 3.0 0.0 2.5 0.6 0.513 
40S ribosomal protein 
S10  
RS10_BOVIN 
(+1) 19 kDa 0.0 0.0 1.8 3.7 0.0 0.0 4.7 2.5 1.3 0.779 0.0 0.8 0.0 1.7 0.4 0.468 
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Weight 1 2 3 4 1 2 3 4 Fold   P-value 1 2 3 4 Fold   P-value 
S-formylglutathione 
hydrolase  ESTD_HUMAN 31 kDa 0.0 0.0 0.0 1.5 0.0 0.0 2.9 0.0 2.0 0.680 0.0 0.0 0.0 0.0 0.0 0.391 
Tetranectin  TETN_BOVIN 22 kDa 0.0 3.4 1.8 0.0 3.9 4.3 0.4 1.2 1.9 0.408 4.1 1.5 2.3 0.0 1.5 0.597 
Peroxiredoxin-2  
PRDX2_HUMAN 




(+2) 74 kDa 0.0 0.0 1.8 0.0 0.0 0.0 2.2 0.0 1.2 0.903 0.0 6.1 0.0 4.2 5.6 0.266 
Glycine--tRNA ligase  SYG_HUMAN 83 kDa 0.0 0.0 1.2 5.1 0.0 0.0 5.4 2.5 1.2 0.835 0.0 1.5 0.0 0.8 0.4 0.481 
Insulin-like growth 
factor-binding protein 2  IBP2_HUMAN 35 kDa 0.0 0.0 1.2 2.9 0.6 0.0 0.7 1.2 0.6 0.611 0.0 2.3 0.0 0.0 0.5 0.622 
Protein CDV3 homolog  CDV3_HUMAN 27 kDa 0.0 2.3 1.2 2.9 0.0 1.4 3.3 1.2 0.9 0.897 0.0 4.6 0.0 0.8 0.8 0.844 
Ribonuclease inhibitor  RINI_HUMAN 50 kDa 0.0 1.1 0.6 5.1 0.0 0.0 3.6 2.5 0.9 0.897 0.0 1.5 0.0 2.5 0.6 0.609 
Band 4.1-like protein 3  E41L3_HUMAN 121 kDa 0.0 1.1 1.2 4.4 0.0 1.4 2.5 3.7 1.1 0.860 0.0 3.8 1.1 4.2 1.3 0.691 
Septin-9  SEPT9_HUMAN 65 kDa 0.0 3.4 0.6 3.7 0.0 2.9 1.8 2.5 0.9 0.907 0.0 3.8 0.0 4.2 1.0 0.969 
LIM and SH3 domain 
protein 1  LASP1_PONAB 30 kDa 0.0 1.1 0.6 3.7 0.0 0.0 3.3 1.2 0.8 0.843 0.0 1.5 0.0 1.7 0.6 0.574 
Superoxide dismutase 
[Cu-Zn]  SODC_HUMAN 16 kDa 0.0 0.0 4.2 1.5 0.0 0.0 2.9 1.2 0.7 0.758 0.0 1.5 0.0 0.0 0.3 0.385 
40S ribosomal protein 
S15a  
RS15A_BOVIN 
(+1) 15 kDa 0.0 0.0 0.6 3.7 0.0 0.0 2.9 2.5 1.3 0.826 0.0 0.8 0.0 5.8 1.5 0.743 
Proteasome subunit 
beta type-7  PSB7_HUMAN 30 kDa 0.0 1.1 1.8 3.7 0.0 1.4 1.1 2.5 0.8 0.673 0.0 3.8 0.0 3.3 1.1 0.928 
60S ribosomal protein 
L14  RL14_HUMAN 23 kDa 0.0 0.0 0.0 5.9 0.0 0.0 1.5 4.9 1.1 0.950 0.0 1.5 0.0 3.3 0.8 0.882 
Proteasome subunit 
alpha type-6  PSA6_BOVIN 27 kDa 0.0 0.0 0.0 2.9 0.0 0.0 4.4 2.5 2.3 0.483 0.0 1.5 0.0 0.8 0.8 0.865 
60S ribosomal protein 
L17  
RL17_BOVIN 
(+2) 21 kDa 0.0 0.0 0.0 6.6 0.0 0.0 0.0 2.5 0.4 0.589 0.0 0.0 0.0 7.5 1.1 0.935 
Eukaryotic translation 
initiation factor 2 
subunit 3  
IF2G_HUMAN 
(+1) 51 kDa 0.0 0.0 0.0 8.1 0.0 0.0 1.5 2.5 0.5 0.650 0.0 2.3 0.0 2.5 0.6 0.719 
Lupus La protein  LA_HUMAN 47 kDa 0.0 1.1 0.6 3.7 0.0 1.4 1.5 2.5 1.0 0.985 1.4 3.0 0.0 3.3 1.4 0.625 
40S ribosomal protein 
S15  
RS15_CHICK 
(+1) 17 kDa 0.0 0.0 1.2 4.4 0.0 0.0 1.1 6.2 1.3 0.830 0.0 2.3 1.1 5.0 1.5 0.659 
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Weight 1 2 3 4 1 2 3 4 Fold   P-value 1 2 3 4 Fold   P-value 
Exportin-2  
XPO2_HUMAN 
(+3) 110 kDa 0.0 2.3 0.0 4.4 0.0 0.0 0.4 0.0 0.1 0.232 0.0 3.0 0.0 2.5 0.8 0.834 
Nucleolin  
NUCL_HUMAN 
(+2) 77 kDa 0.0 0.0 0.0 8.8 0.0 0.0 2.2 0.0 0.2 0.512 0.0 0.0 0.0 6.6 0.8 0.850 
Transthyretin  TTHY_BOVIN 16 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Hsp90 co-chaperone 
Cdc37  CDC37_HUMAN 44 kDa 0.0 2.3 2.4 1.5 0.0 1.4 1.5 2.5 0.9 0.793 2.7 1.5 2.3 1.7 1.3 0.462 
RNA-binding protein 
EWS  EWS_MOUSE 68 kDa 0.0 2.3 1.2 2.9 0.0 1.4 1.1 2.5 0.8 0.675 0.0 2.3 1.1 1.7 0.8 0.688 
Procollagen-lysine,2-
oxoglutarate 5-





(+1) 47 kDa 0.0 1.1 0.6 3.7 0.0 1.4 2.5 1.2 1.0 0.957 0.0 1.5 0.0 2.5 0.7 0.740 
Histone H2B type 1-
C/E/F/G/I  
H2B1C_HUMAN 
(+16) 14 kDa 0.0 0.0 1.2 0.7 0.6 0.0 1.8 0.0 1.2 0.847 0.0 3.0 0.0 1.7 2.4 0.435 
Elongation factor 1-beta  
EF1B_HUMAN 
(+1) 25 kDa 0.0 1.1 0.6 2.9 0.0 0.0 3.3 1.2 1.0 0.963 0.0 3.8 0.0 3.3 1.5 0.637 
Keratin, type II 
cytoskeletal 6A  K2C6A_HUMAN 60 kDa 0.0 0.0 0.0 0.0 0.6 0.0 12.3 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Dihydropyrimidinase-
related protein 2  DPYL2_HUMAN 62 kDa 0.0 0.0 1.2 0.0 0.0 0.0 8.0 0.0 6.6 0.461 0.0 0.0 0.0 0.0 0.0 0.391 
Apolipoprotein M  APOM_HUMAN 21 kDa 1.8 1.1 0.6 0.7 0.0 1.4 0.0 0.0 0.3 0.167 0.0 0.8 0.0 0.8 0.4 0.107 
Keratin, type II 
cytoskeletal 2 epidermal  K22E_HUMAN 65 kDa 1.8 0.0 0.0 0.0 1.1 8.6 8.0 4.9 12.5 0.052 0.0 0.0 0.0 2.5 1.4 0.834 
Proteasome subunit 
alpha type-3  
PSA3_HUMAN 
(+3) 28 kDa 0.0 2.3 1.2 2.2 0.0 2.9 2.2 2.5 1.3 0.608 2.7 3.0 0.0 2.5 1.5 0.495 
Heat shock 70 kDa 
protein 1A/1B  
HSP71_HUMAN 
(+4) 70 kDa 0.0 8.0 1.8 4.4 1.1 5.7 5.4 6.2 1.3 0.634 6.8 3.8 3.4 6.6 1.5 0.451 
Dihydropyrimidinase-
related protein 3  DPYL3_HUMAN 62 kDa 0.0 1.1 1.2 1.5 0.0 0.0 4.4 1.2 1.5 0.706 0.0 1.5 0.0 0.8 0.6 0.482 
6-phosphofructokinase 
type C  K6PP_HUMAN 86 kDa 0.0 0.0 1.2 1.5 0.0 0.0 4.7 1.2 2.2 0.530 0.0 1.5 0.0 0.8 0.9 0.882 
Apolipoprotein D  APOD_BOVIN 21 kDa 0.0 1.1 0.0 0.7 3.3 1.4 0.4 0.0 2.7 0.369 0.0 0.8 1.1 0.8 1.5 0.591 
Calumenin  
CALU_HUMAN 
(+1) 37 kDa 0.0 0.0 0.0 1.5 0.0 0.0 1.8 2.5 2.9 0.383 0.0 4.6 0.0 2.5 4.8 0.302 
 20 




Weight 1 2 3 4 1 2 3 4 Fold   P-value 1 2 3 4 Fold  P-value 
T-complex protein 1 
subunit zeta  
TCPZ_HUMAN 
(+1) 58 kDa 0.0 0.0 0.0 4.4 0.0 0.0 2.9 1.2 0.9 0.959 0.0 0.8 0.0 1.7 0.5 0.694 
Microtubule-associated 
protein 1B  
MAP1B_HUMA
N 271 kDa 0.0 0.0 0.0 11.8 0.0 0.0 0.0 0.0 N/A N/A 0.0 0.0 0.0 1.7 0.1 0.455 
Tyrosine-protein kinase 
receptor UFO  UFO_HUMAN 98 kDa 3.6 0.0 1.2 1.5 0.6 0.0 1.1 2.5 0.7 0.574 1.4 0.0 1.1 0.8 0.5 0.412 
Cathelicidin-4  CTHL4_BOVIN 16 kDa 1.8 1.1 0.0 1.5 0.0 1.4 0.7 0.0 0.5 0.321 0.0 1.5 0.0 0.8 0.5 0.372 
1,4-alpha-glucan-
branching enzyme  GLGB_HUMAN 80 kDa 0.0 2.3 0.6 2.9 0.0 1.4 1.8 2.5 1.0 0.974 0.0 1.5 0.0 1.7 0.5 0.460 
Eukaryotic translation 
initiation factor 2A  EIF2A_HUMAN 65 kDa 0.0 1.1 0.0 4.4 0.0 1.4 1.1 2.5 0.9 0.908 0.0 3.0 0.0 2.5 1.0 0.996 
Glucosidase 2 subunit 
beta  GLU2B_HUMAN 59 kDa 0.0 0.0 0.0 1.5 0.0 0.0 1.8 2.5 2.9 0.383 1.4 3.8 1.1 1.7 5.4 0.073 
SAP domain-containing 
ribonucleoprotein  SARNP_HUMAN 24 kDa 0.0 0.0 0.0 2.9 0.0 0.0 2.2 0.0 0.7 0.842 0.0 1.5 0.0 0.8 0.8 0.865 
60S acidic ribosomal 
protein P2  
RLA2_HUMAN 
(+1) 12 kDa 0.0 0.0 0.0 8.1 0.0 0.0 0.4 1.2 0.2 0.483 0.0 0.0 0.0 5.8 0.7 0.827 
60S ribosomal protein 
L34  
RL34_HUMAN 
(+5) 13 kDa 0.0 0.0 0.0 3.7 0.0 0.0 0.7 4.9 1.5 0.754 0.0 0.0 0.0 5.0 1.4 0.841 
40S ribosomal protein 
S11  
RS11_BOVIN 
(+1) 18 kDa 0.0 0.0 0.0 3.7 0.0 0.0 2.5 3.7 1.7 0.642 0.0 0.0 0.0 3.3 0.9 0.945 
Actin-related protein 2/3 
complex subunit 2  
ARPC2_HUMAN 
(+3) 34 kDa 0.0 0.0 0.6 0.0 0.0 0.0 5.1 0.0 8.4 0.445 0.0 2.3 0.0 0.0 3.8 0.523 
Heterogeneous nuclear 
ribonucleoprotein A3  
ROA3_HUMAN 
(+1) 40 kDa 0.0 1.1 1.8 5.9 0.0 1.4 7.6 1.2 1.2 0.872 0.0 3.8 0.0 0.8 0.5 0.529 
Drebrin-like protein  DBNL_HUMAN 48 kDa 0.0 0.0 0.6 4.4 0.0 1.4 2.9 1.2 1.1 0.914 0.0 2.3 1.1 2.5 1.2 0.863 
Y-box-binding protein 3  YBOX3_HUMAN 40 kDa 0.0 0.0 0.6 5.1 0.0 1.4 1.5 4.9 1.4 0.762 0.0 3.8 0.0 4.2 1.4 0.757 
Heterogeneous nuclear 
ribonucleoprotein Q  HNRPQ_MOUSE 70 kDa 0.0 0.0 0.6 2.9 0.0 0.0 2.9 2.5 1.5 0.679 0.0 3.0 0.0 1.7 1.3 0.786 
Actin-related protein 2-A  
ARP2A_DANRE 
(+7) 45 kDa 0.0 0.0 0.6 2.2 0.0 0.0 7.3 0.0 2.6 0.592 0.0 0.8 0.0 0.0 0.3 0.410 
Keratin, type I 
cytoskeletal 13  K1C13_HUMAN 50 kDa 0.0 0.0 0.0 0.0 0.0 0.0 11.2 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Tyrosine-protein kinase 
receptor Tie-1  TIE1_HUMAN 125 kDa 1.8 2.3 0.6 1.5 0.0 0.0 0.4 0.0 0.1 0.023 1.4 1.5 1.1 0.0 0.7 0.318 
Tissue-type plasminogen 
activator  TPA_HUMAN 63 kDa 1.8 0.0 0.6 2.9 0.6 2.9 1.8 1.2 1.2 0.746 1.4 3.0 3.4 0.8 1.6 0.401 
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Weight 1 2 3 4 1 2 3 4 Fold  P-value 1 2 3 4 Fold   P-value 
40S ribosomal protein 
S28  RS28_BOVIN 8 kDa 0.0 1.1 0.0 2.2 0.0 0.0 2.2 2.5 1.4 0.719 0.0 1.5 0.0 4.2 1.7 0.626 
BAG family molecular 
chaperone regulator 3  BAG3_HUMAN 62 kDa 0.0 1.1 0.6 2.2 0.0 1.4 0.7 0.0 0.5 0.472 1.4 2.3 0.0 0.8 1.1 0.851 
Proteasome subunit 
beta type-2  PSB2_HUMAN 23 kDa 0.0 1.1 1.2 3.7 0.0 1.4 1.1 2.5 0.8 0.790 0.0 3.0 0.0 1.7 0.8 0.766 
40S ribosomal protein 
S5a  
RS5A_DROME 
(+1) 25 kDa 0.0 0.0 2.4 2.2 0.6 0.0 1.8 2.5 1.0 0.955 0.0 0.8 0.0 1.7 0.5 0.510 
Threonine--tRNA ligase, 
cytoplasmic  SYTC_HUMAN 83 kDa 0.0 1.1 1.2 0.7 0.0 2.9 4.0 0.0 2.2 0.429 1.4 1.5 1.1 0.0 1.3 0.618 
Cell surface glycoprotein 
MUC18  
MUC18_HUMA




(+1) 57 kDa 0.0 1.1 0.0 2.9 0.0 1.4 3.6 1.2 1.5 0.609 0.0 2.3 0.0 2.5 1.2 0.867 
Calpastatin  ICAL_HUMAN 77 kDa 0.0 0.0 0.0 2.9 0.0 0.0 0.7 1.2 0.7 0.772 0.0 0.8 0.0 1.7 0.8 0.882 
Neutral alpha-
glucosidase AB  
GANAB_HUMA
N (+1) 107 kDa 0.0 0.0 0.0 0.7 0.0 1.4 2.2 0.0 4.9 0.283 1.4 1.5 0.0 0.8 5.1 0.119 
Proteasome subunit 
alpha type-7  PSA7_HUMAN 28 kDa 0.0 0.0 1.8 4.4 0.0 0.0 3.3 0.0 0.5 0.597 0.0 0.8 0.0 0.0 0.1 0.283 
Fructose-bisphosphate 
aldolase C  
ALDOC_HUMA
N (+2) 39 kDa 0.0 0.0 2.4 0.7 0.0 0.0 4.4 0.0 1.4 0.818 0.0 2.3 0.0 1.7 1.2 0.819 
Tryptophan--tRNA 
ligase, cytoplasmic  
SYWC_HUMAN 
(+1) 53 kDa 0.0 0.0 0.6 0.0 0.0 0.0 4.7 0.0 7.8 0.449 0.0 0.0 0.0 0.0 0.0 0.391 
40S ribosomal protein 
S19  
RS19_BOVIN 
(+2) 16 kDa 0.0 0.0 1.2 0.7 0.0 0.0 4.4 2.5 3.5 0.338 0.0 0.8 0.0 0.8 0.8 0.821 
Phosphoserine 
aminotransferase  SERC_HUMAN 40 kDa 0.0 1.1 0.6 3.7 0.0 0.0 2.9 0.0 0.5 0.583 0.0 0.8 0.0 1.7 0.4 0.447 
Inosine-5'-
monophosphate 
dehydrogenase 2  
IMDH2_HUMA
N 56 kDa 0.0 0.0 2.4 4.4 0.0 0.0 3.6 0.0 0.5 0.588 0.0 1.5 0.0 1.7 0.5 0.475 
Heterogeneous nuclear 
ribonucleoprotein A/B  ROAA_MOUSE 31 kDa 0.0 0.0 3.0 5.9 0.0 0.0 4.4 3.7 0.9 0.911 1.4 5.3 0.0 5.8 1.4 0.672 
Protein S100-A13  S10AD_HUMAN 11 kDa 0.0 1.1 0.6 2.2 0.0 1.4 1.5 1.2 1.0 0.946 0.0 1.5 0.0 2.5 1.0 0.986 
Coronin-1C  COR1C_HUMAN 53 kDa 0.0 1.1 0.6 2.2 0.0 1.4 2.9 1.2 1.4 0.614 0.0 1.5 1.1 1.7 1.1 0.886 
UV excision repair 
protein RAD23 homolog 
B  RD23B_HUMAN 43 kDa 0.0 2.3 0.0 5.1 0.0 0.0 2.5 0.0 0.3 0.419 1.4 1.5 0.0 0.0 0.4 0.433 
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Weight 1 2 3 4 1 2 3 4 Fold   P-value 1 2 3 4 Fold  P-value 
Importin-5  IPO5_HUMAN 124 kDa 0.0 1.1 0.0 4.4 0.0 0.0 1.5 1.2 0.5 0.556 0.0 1.5 0.0 1.7 0.6 0.629 
Eukaryotic initiation 
factor 4A-II  
IF4A2_BOVIN 
(+1) 46 kDa 0.0 0.0 7.3 8.1 0.0 0.0 11.6 8.6 1.3 0.755 0.0 9.1 0.0 8.3 1.1 0.883 
Thioredoxin reductase 1, 
cytoplasmic  
TRXR1_HUMAN 
(+1) 71 kDa 0.0 0.0 1.8 0.0 0.6 0.0 4.0 0.0 2.5 0.554 0.0 0.0 0.0 0.0 0.0 0.391 
60S acidic ribosomal 
protein P0  
RLA0_HUMAN 
(+4) 34 kDa 0.0 0.0 0.0 6.6 0.0 0.0 1.8 2.5 0.6 0.758 0.0 0.0 0.0 4.2 0.6 0.765 
Rho-related GTP-binding 
protein RhoC  RHOC_BOVIN 22 kDa 0.0 1.1 1.2 2.2 0.0 1.4 2.2 1.2 1.1 0.914 0.0 1.5 0.0 1.7 0.7 0.612 
BTB/POZ domain-
containing protein 
KCTD12  KCD12_HUMAN 36 kDa 0.0 0.0 1.8 3.7 0.0 1.4 2.5 0.0 0.7 0.737 0.0 1.5 1.1 1.7 0.8 0.773 
Src substrate cortactin  SRC8_HUMAN 62 kDa 0.0 1.1 0.6 2.9 0.0 0.0 2.9 2.5 1.1 0.872 0.0 1.5 0.0 0.8 0.5 0.462 
Chloride intracellular 
channel protein 4  
CLIC4_HUMAN 
(+4) 29 kDa 0.0 1.1 1.8 2.9 0.0 0.0 2.9 0.0 0.5 0.462 0.0 1.5 0.0 0.8 0.4 0.272 
Complement factor H  CFAH_BOVIN 140 kDa 0.0 1.1 1.2 0.7 3.3 0.0 0.0 0.0 1.1 0.949 1.4 0.0 0.0 0.0 0.4 0.369 
Hepatoma-derived 
growth factor  HDGF_HUMAN 27 kDa 0.0 0.0 0.0 4.4 0.0 0.0 1.5 3.7 1.2 0.901 0.0 3.0 0.0 1.7 1.1 0.959 
40S ribosomal protein 
S23  
RS23_BOVIN 
(+5) 16 kDa 0.0 0.0 0.0 1.5 0.0 0.0 2.2 3.7 4.0 0.322 0.0 0.0 0.0 2.5 1.7 0.739 
Asparagine--tRNA ligase, 




(+1) 55 kDa 0.0 0.0 0.6 1.5 0.0 1.4 1.5 1.2 2.0 0.339 1.4 1.5 1.1 2.5 3.1 0.053 
40S ribosomal protein S7  RS7_BOVIN 22 kDa 0.0 0.0 1.2 1.5 0.6 0.0 1.8 1.2 1.3 0.694 0.0 1.5 0.0 3.3 1.8 0.571 
Elongation factor 1-delta  EF1D_HUMAN 31 kDa 0.0 0.0 0.0 5.1 0.0 0.0 2.2 2.5 0.9 0.934 0.0 1.5 0.0 2.5 0.8 0.851 
Serum albumin  ALBU_SHEEP 69 kDa 596.7 332.1 0.0 111.8 502.4 0.0 125.2 0.0 0.6 0.582 0.0 235.4 0.0 217.5 0.4 0.370 
ADP-ribosylation factor 
4  ARF4_HUMAN 21 kDa 0.0 2.3 0.6 2.2 0.0 1.4 1.5 2.5 1.1 0.936 0.0 1.5 0.0 2.5 0.8 0.758 
Microtubule-associated 
protein RP/EB family 
member 1  
MARE1_HUMA
N 30 kDa 0.0 1.1 0.0 0.0 0.0 0.0 3.3 0.0 2.9 0.575 0.0 0.0 0.0 0.0 0.0 0.391 
Stathmin  
STMN1_BOVIN 
(+1) 17 kDa 0.0 0.0 1.2 1.5 0.0 0.0 4.4 3.7 3.0 0.343 0.0 1.5 0.0 0.8 0.9 0.882 
 23 








(+1) 41 kDa 0.0 0.0 0.0 5.1 0.0 0.0 2.2 0.0 0.4 0.623 0.0 0.0 0.0 1.7 0.3 0.558 
Puromycin-sensitive 
aminopeptidase  PSA_HUMAN 103 kDa 0.0 0.0 0.6 1.5 0.0 0.0 2.9 0.0 1.4 0.809 0.0 0.8 0.0 0.0 0.4 0.447 
NSFL1 cofactor p47  NSF1C_HUMAN 41 kDa 0.0 0.0 0.6 2.9 0.0 1.4 1.1 1.2 1.1 0.949 0.0 2.3 0.0 2.5 1.3 0.766 
60S ribosomal protein 
L11  
RL11_BOVIN 
(+1) 20 kDa 0.0 0.0 1.8 0.7 0.0 0.0 2.2 3.7 2.3 0.450 0.0 0.8 0.0 2.5 1.3 0.819 
DNA-dependent protein 
kinase catalytic subunit  PRKDC_HUMAN 469 kDa 0.0 0.0 0.0 2.2 0.0 0.0 0.0 2.5 1.1 0.940 0.0 2.3 0.0 3.3 2.5 0.434 
Serpin B9  SPB9_HUMAN 42 kDa 0.0 0.0 0.6 0.7 0.0 0.0 3.6 1.2 3.6 0.383 0.0 0.8 0.0 0.0 0.6 0.613 
Septin-7  
SEPT7_BOVIN 
(+4) 51 kDa 0.0 0.0 0.0 2.2 0.0 0.0 2.5 0.0 1.2 0.924 0.0 0.0 0.0 0.8 0.4 0.592 
60S ribosomal protein 
L38  
RL38_BOVIN 
(+2) 8 kDa 0.0 0.0 1.8 0.0 0.0 0.0 2.5 0.0 1.4 0.825 0.0 0.0 0.0 0.0 0.0 0.391 









(+1) 59 kDa 0.0 1.1 0.0 2.2 0.0 1.4 2.2 1.2 1.4 0.611 0.0 0.8 0.0 0.0 0.2 0.318 
26S proteasome non-
ATPase regulatory 
subunit 11  
PSD11_BOVIN 




(+5) 24 kDa 0.0 0.0 0.6 2.9 0.0 0.0 1.8 1.2 0.9 0.886 0.0 0.8 0.0 2.5 0.9 0.938 
Cadherin-5  
CADH5_HUMA
N 88 kDa 0.0 1.1 3.0 0.0 0.0 0.0 2.9 1.2 1.0 0.993 0.0 0.8 0.0 0.0 0.2 0.323 
40S ribosomal protein S6  
RS6_HUMAN 
(+2) 29 kDa 0.0 0.0 0.6 3.7 0.0 0.0 0.7 2.5 0.7 0.806 0.0 0.0 0.0 4.2 1.0 0.982 
Histone H1.2  
H12_HUMAN 
(+8) 21 kDa 0.0 0.0 0.0 2.9 0.0 0.0 1.5 2.5 1.3 0.807 0.0 1.5 0.0 1.7 1.1 0.948 
60S ribosomal protein 
L35a  
RL35A_HUMAN 
(+2) 13 kDa 0.0 0.0 0.0 3.7 0.0 0.0 0.4 3.7 1.1 0.943 0.0 0.0 0.0 3.3 0.9 0.945 
Fermitin family homolog 
3  URP2_HUMAN 76 kDa 0.0 0.0 0.0 2.2 0.0 0.0 2.5 0.0 1.2 0.924 0.0 0.0 0.0 0.0 0.0 0.391 
60S ribosomal protein 
L7a  
RL7A_HUMAN 
(+1) 30 kDa 0.0 0.0 0.0 5.9 0.0 0.0 1.1 3.7 0.8 0.879 0.0 0.0 0.0 2.5 0.4 0.623 
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Weight 1 2 3 4 1 2 3 4 Fold   P-value 1 2 3 4 Fold   P-value 
Protein AHNAK2  
AHNK2_HUMA
N 617 kDa 0.0 0.0 0.0 3.7 0.0 0.0 2.5 1.2 1.0 0.984 0.0 1.5 0.0 0.0 0.4 0.616 
60S ribosomal protein L4  
RL4_HUMAN 
(+1) 48 kDa 0.0 0.0 0.0 1.5 0.0 0.0 1.8 0.0 1.2 0.888 0.0 0.0 0.0 2.5 1.7 0.739 
Cellular nucleic acid-
binding protein  
CNBP_HUMAN 
(+1) 19 kDa 0.0 1.1 0.6 2.2 0.0 1.4 1.8 1.2 1.1 0.836 0.0 1.5 0.0 0.8 0.6 0.527 
Peptidyl-prolyl cis-trans 
isomerase FKBP4  FKBP4_HUMAN 52 kDa 0.0 0.0 0.6 4.4 0.0 1.4 1.1 0.0 0.5 0.611 1.4 0.8 0.0 1.7 0.8 0.799 
60S ribosomal protein 
L15  RL15_BOVIN 24 kDa 0.0 0.0 0.0 2.9 0.0 0.0 1.5 0.0 0.5 0.671 0.0 0.0 0.0 2.5 0.8 0.911 
Calpain small subunit 1  
CPNS1_HUMAN 
(+3) 28 kDa 0.0 2.3 0.6 2.9 0.0 1.4 0.7 2.5 0.8 0.741 0.0 1.5 0.0 1.7 0.5 0.460 
High mobility group 
protein HMGI-C  
HMGA2_HUMA
N 12 kDa 0.0 0.0 0.0 2.2 0.0 0.0 0.7 3.7 2.0 0.617 0.0 2.3 1.1 1.7 2.3 0.367 
Hypoxia up-regulated 
protein 1  
HYOU1_HUMA
N 111 kDa 0.0 0.0 1.2 0.7 0.0 0.0 0.4 2.5 1.5 0.755 0.0 2.3 1.1 2.5 3.0 0.194 
Phenylalanine--tRNA 
ligase alpha subunit  
SYFA_HUMAN 
(+1) 58 kDa 0.0 1.1 0.6 2.9 0.0 0.0 0.7 2.5 0.7 0.679 0.0 3.0 0.0 2.5 1.2 0.845 
60S ribosomal protein 
L23a  RL23A_BOVIN 18 kDa 0.0 0.0 0.0 3.7 0.0 0.0 1.5 2.5 1.1 0.959 0.0 0.8 0.0 1.7 0.7 0.769 
Heterogeneous nuclear 
ribonucleoprotein L  HNRPL_HUMAN 64 kDa 0.0 1.1 0.0 3.7 0.0 0.0 1.1 0.0 0.2 0.369 0.0 0.8 0.0 0.8 0.3 0.427 
Eukaryotic translation 
initiation factor 4H  
IF4H_HUMAN 
(+3) 27 kDa 0.0 0.0 0.0 3.7 0.0 0.0 1.1 2.5 1.0 0.978 0.0 1.5 0.0 2.5 1.1 0.943 
Alanine--tRNA ligase, 
cytoplasmic  SYAC_HUMAN 107 kDa 0.0 1.1 0.0 4.4 0.0 0.0 1.5 1.2 0.5 0.556 0.0 0.8 0.0 1.7 0.4 0.523 
Proteasome subunit 
alpha type-5  
PSA5_BOVIN 
(+1) 26 kDa 0.0 0.0 0.6 1.5 0.0 0.0 3.6 1.2 2.3 0.493 0.0 0.0 0.0 0.8 0.4 0.477 
Coatomer subunit beta'  COPB2_HUMAN 102 kDa 0.0 0.0 0.0 5.9 0.0 0.0 0.4 0.0 0.1 0.418 0.0 0.8 0.0 1.7 0.4 0.605 
Thyroxine-binding 
globulin  THBG_BOVIN 46 kDa 0.0 0.0 0.0 0.0 4.4 0.0 0.0 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Valine--tRNA ligase  SYVC_HUMAN 140 kDa 0.0 1.1 0.6 2.2 0.0 1.4 0.4 0.0 0.5 0.391 0.0 0.8 1.1 0.8 0.7 0.587 
UDP-N-
acetylhexosamine 
pyrophosphorylase  UAP1_HUMAN 59 kDa 0.0 1.1 0.0 1.5 0.0 0.0 1.5 1.2 1.0 0.975 0.0 1.5 0.0 2.5 1.5 0.649 
60S ribosomal protein 
L22  
RL22_HUMAN 
(+2) 15 kDa 0.0 0.0 0.0 4.4 0.0 0.0 1.5 0.0 0.3 0.562 0.0 0.8 0.0 2.5 0.7 0.826 
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Weight 1 2 3 4 1 2 3 4 Fold   P-value 1 2 3 4 Fold  P-value 
Probable ATP-
dependent RNA helicase 
DDX17  
DDX17_HUMAN 
(+1) 80 kDa 0.0 0.0 0.6 1.5 0.0 0.0 2.2 3.7 2.8 0.384 0.0 1.5 0.0 2.5 1.9 0.524 
Importin subunit beta-1  IMB1_HUMAN 97 kDa 0.0 1.1 0.6 3.7 0.0 0.0 0.7 0.0 0.1 0.243 0.0 0.8 0.0 1.7 0.4 0.447 
Ubiquitin carboxyl-
terminal hydrolase 14  
UBP14_HUMAN 




(+1) 39 kDa 0.0 2.3 2.4 4.4 0.0 0.0 2.2 2.5 0.5 0.361 0.0 2.3 0.0 2.5 0.5 0.378 
40S ribosomal protein 
S17-like  
RS17L_HUMAN 
(+4) 16 kDa 0.0 0.0 0.6 2.2 0.0 0.0 1.5 2.5 1.4 0.741 0.0 0.0 0.0 1.7 0.6 0.682 
Phosphatidylethanolami
ne-binding protein 1  PEBP1_HUMAN 21 kDa 0.0 0.0 2.4 0.7 0.0 0.0 3.6 0.0 1.1 0.917 0.0 0.8 0.0 0.0 0.2 0.381 
Polymerase I and 
transcript release factor  PTRF_HUMAN 43 kDa 0.0 0.0 0.0 6.6 0.0 0.0 1.1 0.0 0.2 0.467 0.0 0.0 0.0 1.7 0.3 0.515 
Tubulin-specific 
chaperone A  TBCA_HUMAN 13 kDa 0.0 0.0 1.2 3.7 0.0 0.0 2.9 0.0 0.6 0.676 0.0 0.0 0.0 0.0 0.0 0.253 
Caprin-1  CAPR1_HUMAN 78 kDa 0.0 1.1 0.0 2.2 0.0 1.4 0.7 2.5 1.4 0.683 0.0 1.5 1.1 0.8 1.0 0.959 
Epididymal secretory 
protein E1  NPC2_HUMAN 17 kDa 1.8 0.0 0.6 2.2 0.0 0.0 0.0 1.2 0.3 0.217 1.4 2.3 0.0 1.7 1.1 0.817 
60S ribosomal protein L9  
RL9_HUMAN 
(+3) 22 kDa 0.0 1.1 0.0 0.7 0.0 0.0 1.8 1.2 1.6 0.609 0.0 0.8 0.0 0.8 0.8 0.851 
Serpin H1  
SERPH_HUMAN 
(+1) 46 kDa 0.0 0.0 0.0 0.7 1.1 0.0 1.8 1.2 5.7 0.107 0.0 3.0 0.0 1.7 6.4 0.273 
Paxillin  PAXI_HUMAN 65 kDa 0.0 0.0 0.0 2.9 0.0 0.0 1.1 0.0 0.4 0.588 0.0 0.8 0.0 1.7 0.8 0.882 
Transcription 
intermediary factor 1-
beta  TIF1B_HUMAN 89 kDa 0.0 0.0 0.0 2.2 0.0 0.0 2.9 0.0 1.3 0.855 0.0 0.8 0.0 0.8 0.7 0.809 
Mitotic checkpoint 
protein BUB3  
BUB3_HUMAN 




(+4) 23 kDa 0.0 0.0 0.6 0.7 0.0 0.0 2.5 0.0 1.9 0.678 0.0 2.3 0.0 0.0 1.7 0.718 
Translationally-
controlled tumor protein  
TCTP_HUMAN 
(+2) 20 kDa 0.0 0.0 0.0 1.5 0.0 0.0 2.9 0.0 2.0 0.680 0.0 0.0 0.0 0.8 0.6 0.721 
Complement 
component C7  CO7_BOVIN 93 kDa 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 N/A N/A 0.0 0.0 1.1 0.0 N/A N/A 
Hemoglobin subunit 
beta  HBB_BOVIN 16 kDa 0.0 18.3 11.5 0.0 16.6 0.0 5.4 0.0 0.7 0.759 19.2 0.0 18.1 0.0 1.3 0.798 
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Weight 1 2 3 4 1 2 3 4 Fold   P-value 1 2 3 4 Fold   P-value 
Proliferating cell nuclear 
antigen  
PCNA_HUMAN 
(+2) 29 kDa 0.0 0.0 1.8 0.7 0.0 0.0 1.8 1.2 1.2 0.850 0.0 0.8 0.0 0.8 0.6 0.644 
60S ribosomal protein 
L31  RL31_BOVIN 14 kDa 0.0 0.0 0.6 1.5 0.0 0.0 1.5 0.0 0.7 0.766 0.0 0.0 0.0 1.7 0.8 0.854 
Protein transport 
protein Sec23A  SC23A_BOVIN 87 kDa 0.0 0.0 0.0 1.5 0.0 0.0 3.3 0.0 2.2 0.642 0.0 0.8 0.0 0.8 1.1 0.948 
S-adenosylmethionine 
synthase isoform type-2  
METK2_HUMA
N (+2) 44 kDa 0.0 0.0 0.0 3.7 0.0 0.0 2.2 0.0 0.6 0.740 0.0 0.0 0.0 1.7 0.5 0.642 
X-ray repair cross-
complementing protein 
5  XRCC5_HUMAN 83 kDa 0.0 0.0 0.6 0.0 0.0 0.0 4.0 0.0 6.6 0.461 0.0 0.8 0.0 0.0 1.3 0.879 
26S protease regulatory 
subunit 7  
PRS7_BOVIN 





(+3) 46 kDa 0.0 0.0 0.6 5.1 0.0 0.0 1.5 0.0 0.3 0.460 0.0 0.0 0.0 0.0 0.0 0.332 
Laminin subunit alpha-5  
LAMA5_HUMA
N 400 kDa 0.0 0.0 0.6 0.0 0.0 1.4 0.4 1.2 5.0 0.179 0.0 1.5 0.0 0.8 3.9 0.334 
Protein transport 
protein Sec24C  SC24C_HUMAN 118 kDa 0.0 0.0 0.6 2.2 0.0 0.0 1.1 2.5 1.3 0.821 0.0 1.5 0.0 1.7 1.1 0.899 
Fatty acid-binding 
protein, epidermal  FABP5_HUMAN 15 kDa 0.0 0.0 0.0 2.2 0.0 0.0 2.5 1.2 1.7 0.650 0.0 0.0 0.0 0.8 0.4 0.592 
Alpha-2-HS-glycoprotein  FETUA_SHEEP 39 kDa 0.0 0.0 44.8 0.0 64.3 0.0 24.7 0.0 2.0 0.581 80.7 44.0 0.0 0.0 2.8 0.416 
E3 ubiquitin/ISG15 ligase 





(+2) 38 kDa 0.0 0.0 0.0 1.5 0.0 0.0 1.1 0.0 0.7 0.842 0.0 0.0 0.0 0.0 N/A N/A 
Actin-related protein 2/3 
complex subunit 4  ARPC4_BOVIN 20 kDa 0.0 0.0 2.4 0.0 0.0 0.0 4.0 0.0 1.6 0.751 0.0 2.3 0.0 0.0 0.9 0.967 
Lactoylglutathione lyase  LGUL_HUMAN 21 kDa 0.0 0.0 1.2 0.0 0.0 0.0 3.6 0.0 3.0 0.565 0.0 0.0 0.0 0.0 N/A N/A 
Cell division control 
protein 42 homolog  
CDC42_BOVIN 
(+2) 21 kDa 1.8 1.1 0.0 0.7 0.0 1.4 1.1 0.0 0.7 0.603 1.4 1.5 1.1 0.0 1.1 0.878 
Heterogeneous nuclear 
ribonucleoprotein H3  
HNRH3_HUMA
N 37 kDa 0.0 1.1 0.6 1.5 0.0 1.4 1.5 1.2 1.3 0.651 0.0 0.8 1.1 1.7 1.1 0.866 
S-phase kinase-
associated protein 1  
SKP1_BOVIN 
(+1) 19 kDa 0.0 1.1 0.6 2.2 0.0 0.0 0.4 1.2 0.4 0.333 0.0 0.8 0.0 0.8 0.4 0.316 
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Weight 1 2 3 4 1 2 3 4 Fold   P-value 1 2 3 4 Fold   P-value 
PEST proteolytic signal-
containing nuclear 
protein  PCNP_HUMAN 19 kDa 0.0 0.0 0.6 1.5 0.0 0.0 1.8 1.2 1.5 0.688 0.0 1.5 0.0 1.7 1.5 0.651 
Keratin, type II  K2C7_HUMAN 51 kDa 0.0 1.1 0.6 1.5 0.0 0.0 3.6 2.5 1.9 0.501 0.0 0.8 0.0 0.0 0.2 0.163 
Glutathione reductase, 
mitochondrial  GSHR_HUMAN 56 kDa 0.0 0.0 0.0 1.5 0.0 0.0 1.5 0.0 1.0 0.993 0.0 0.8 0.0 0.8 1.1 0.948 
60S ribosomal protein 
L36  
RL36_HUMAN 
(+6) 12 kDa 0.0 0.0 0.0 3.7 0.0 0.0 1.1 2.5 1.0 0.978 0.0 0.0 0.0 3.3 0.9 0.945 
Inorganic 
pyrophosphatase  IPYR_HUMAN 33 kDa 0.0 0.0 0.0 2.2 0.0 0.0 2.5 0.0 1.2 0.924 0.0 0.0 0.0 0.0 N/A N/A 
Thioredoxin domain-
containing protein 17  
TXD17_HUMAN 
(+1) 14 kDa 0.0 0.0 1.2 0.0 0.0 0.0 3.3 0.0 2.7 0.588 0.0 0.0 0.0 0.0 N/A N/A 
Programmed cell death 
6-interacting protein  PDC6I_HUMAN 96 kDa 0.0 0.0 0.0 4.4 0.0 0.0 2.2 0.0 0.5 0.671 0.0 0.0 0.0 0.8 0.2 0.480 
Granulins  GRN_HUMAN 64 kDa 0.0 0.0 0.0 1.5 0.0 1.4 0.4 0.0 1.2 0.875 1.4 1.5 0.0 0.0 2.0 0.548 
Hematological and 
neurological expressed 1 
protein  HN1_HUMAN 16 kDa 0.0 1.1 0.6 0.7 0.0 0.0 2.2 0.0 0.9 0.904 0.0 2.3 0.0 0.0 0.9 0.938 
NAD(P)H dehydrogenase 
[quinone] 1  NQO1_HUMAN 31 kDa 0.0 1.1 0.0 2.2 0.0 0.0 1.5 0.0 0.4 0.492 0.0 0.8 0.0 1.7 0.7 0.739 
Glutaredoxin-3  GLRX3_HUMAN 37 kDa 0.0 0.0 0.0 1.5 0.0 0.0 1.5 1.2 1.8 0.592 0.0 1.5 0.0 0.8 1.6 0.687 
Ubiquitin-conjugating 
enzyme E2 K  UBE2K_BOVIN 22 kDa 0.0 0.0 0.0 2.2 0.0 0.0 2.2 0.0 1.0 0.993 0.0 0.8 0.0 0.8 0.7 0.809 
Kinesin-1 heavy chain  KINH_HUMAN 110 kDa 0.0 0.0 0.0 5.1 0.0 0.0 1.1 0.0 0.2 0.492 0.0 0.8 0.0 0.8 0.3 0.542 
RuvB-like 1  
RUVB1_HUMA
N (+1) 50 kDa 0.0 0.0 0.0 0.7 0.0 0.0 2.2 0.0 3.0 0.567 0.0 0.0 0.0 0.0 N/A N/A 
Endoplasmic reticulum 
resident protein 29  ERP29_HUMAN 29 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 N/A N/A 0.0 2.3 0.0 0.0 N/A N/A 
Protein arginine N-
methyltransferase 1  
ANM1_HUMAN 








(+2) 55 kDa 0.0 2.3 0.0 2.9 0.0 1.4 0.7 1.2 0.6 0.611 0.0 0.8 0.0 1.7 0.5 0.457 
26S proteasome non-
ATPase regulatory 
subunit 14  PSDE_HUMAN 35 kDa 0.0 0.0 1.2 1.5 0.0 0.0 1.5 0.0 0.5 0.585 0.0 0.8 0.0 0.8 0.6 0.574 
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Weight 1 2 3 4 1 2 3 4 Fold  P-value 1 2 3 4 Fold   P-value 
Thymosin beta-10  TYB10_HORSE 5 kDa 0.0 1.1 0.0 0.7 1.1 0.0 0.0 0.0 0.6 0.646 0.0 0.8 4.5 2.5 4.1 0.241 
Small nuclear 
ribonucleoprotein Sm 
D2  SMD2_BOVIN 14 kDa 0.0 0.0 0.0 2.2 0.0 0.0 0.7 0.0 0.3 0.562 0.0 0.8 0.0 1.7 1.1 0.940 
Chromobox protein 
homolog 3  
CBX3_HUMAN 
(+1) 21 kDa 0.0 1.1 0.0 2.2 0.0 0.0 1.1 0.0 0.3 0.391 0.0 0.0 0.0 0.0 0.0 0.212 
Actin-1  ACT1_SCHMA 42 kDa 0.0 55.9 53.9 0.0 23.3 0.0 49.7 0.0 0.7 0.660 0.0 67.6 0.0 62.3 1.2 0.845 
60S ribosomal protein L3  
RL3_HUMAN 
(+2) 46 kDa 0.0 0.0 0.0 2.9 0.0 0.0 0.7 0.0 0.2 0.512 0.0 0.0 0.0 0.8 0.3 0.533 
High mobility group 
protein B1  
HMGB1_BOVIN 
(+4) 25 kDa 0.0 0.0 0.0 2.9 0.0 0.0 1.1 0.0 0.4 0.588 0.0 0.0 0.0 2.5 0.8 0.911 
C-1-tetrahydrofolate 
synthase, cytoplasmic  C1TC_HUMAN 102 kDa 0.0 0.0 0.0 1.5 0.0 0.0 2.2 0.0 1.5 0.798 0.0 0.0 0.0 0.8 0.6 0.721 
Serpin B6  
SPB6_HUMAN 
(+1) 43 kDa 0.0 0.0 0.6 0.0 0.0 0.0 4.4 0.0 7.2 0.454 0.0 0.0 0.0 0.0 N/A N/A 
SH3 domain-binding 
glutamic acid-rich-like 
protein 3  
SH3L3_BOVIN 
(+2) 10 kDa 0.0 0.0 0.0 0.0 0.0 0.0 3.3 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Amyloid beta A4 protein  
A4_HUMAN 




methyltransferase  PIMT_HUMAN 25 kDa 0.0 1.1 0.6 1.5 0.0 0.0 0.7 1.2 0.6 0.502 0.0 1.5 0.0 1.7 1.0 0.987 
ELAV-like protein 1  
ELAV1_HUMAN 




(+3) 22 kDa 0.0 0.0 0.6 0.7 0.0 0.0 1.5 1.2 2.0 0.481 0.0 0.8 0.0 0.8 1.2 0.844 
Protein SET  
SET_HUMAN 
(+2) 33 kDa 0.0 0.0 0.0 2.9 0.0 0.0 1.5 1.2 0.9 0.941 0.0 0.0 0.0 2.5 0.8 0.911 
40S ribosomal protein 
S27  RS27_BOVIN 9 kDa 0.0 1.1 0.0 3.7 0.0 0.0 1.5 0.0 0.3 0.421 0.0 0.0 0.0 0.8 0.2 0.337 
RuvB-like 2  
RUVB2_HUMA
N 51 kDa 0.0 0.0 0.0 0.7 0.0 0.0 1.5 0.0 2.0 0.680 0.0 0.0 0.0 0.8 1.1 0.935 
Reticulocalbin-1  RCN1_HUMAN 39 kDa 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 N/A N/A 0.0 0.8 0.0 0.8 N/A N/A 
Catenin alpha-1  CTNA1_HUMAN 100 kDa 0.0 0.0 0.0 2.9 0.0 0.0 0.4 0.0 0.1 0.447 0.0 0.8 0.0 0.8 0.5 0.686 
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Weight 1 2 3 4 1 2 3 4 Fold  P-value 1 2 3 4 Fold  P-value 
Vacuolar protein sorting-
associated protein 35  VPS35_HUMAN 92 kDa 0.0 0.0 0.0 1.5 0.0 0.0 1.5 0.0 1.0 0.993 0.0 0.0 0.0 0.0 N/A N/A 
UMP-CMP kinase  
KCY_HUMAN 
(+4) 22 kDa 0.0 0.0 1.2 0.0 0.0 0.0 2.5 0.0 2.1 0.660 0.0 0.0 0.0 0.0 N/A N/A 
Serine/threonine-
protein phosphatase 2A 
catalytic subunit beta 
isoform  
PP2AB_HUMAN 
(+6) 36 kDa 0.0 0.0 0.6 0.0 0.0 0.0 3.3 0.0 5.4 0.478 0.0 0.0 0.0 0.0 N/A N/A 
Tubulin-folding cofactor 
B  TBCB_HUMAN 27 kDa 0.0 1.1 0.0 2.2 0.0 0.0 0.7 1.2 0.6 0.594 0.0 0.8 1.1 1.7 1.1 0.939 
Cytochrome c  
CYC_GORGO 
(+1) 12 kDa 0.0 0.0 0.0 0.7 0.6 0.0 0.7 0.0 1.7 0.623 0.0 1.5 0.0 0.0 2.1 0.665 
Early endosome antigen 
1  EEA1_HUMAN 162 kDa 0.0 0.0 0.0 1.5 0.0 0.0 0.4 0.0 0.2 0.512 0.0 0.8 0.0 0.8 1.1 0.948 
Ras-related protein Rap-
1  RAP1_PHYPO 21 kDa 0.0 0.0 0.0 3.7 0.0 0.0 0.4 2.5 0.8 0.853 0.0 0.8 0.0 0.8 0.4 0.616 
Sorcin  
SORCN_HUMA
N 22 kDa 0.0 0.0 0.0 2.9 0.0 0.0 0.4 1.2 0.5 0.693 0.0 2.3 0.0 0.8 1.1 0.965 
Phosphoglucomutase-2  PGM2_HUMAN 68 kDa 0.0 0.0 0.0 0.7 0.0 0.0 1.1 2.5 4.8 0.321 0.0 0.8 0.0 1.7 3.3 0.385 
Destrin  
DEST_BOVIN 
(+2) 19 kDa 0.0 0.0 1.2 0.0 0.0 0.0 1.5 0.0 1.2 0.903 0.0 0.8 0.0 0.0 0.6 0.765 
Protein disulfide-
isomerase A6  
PDIA6_HUMAN 
(+1) 48 kDa 0.0 0.0 0.6 0.0 0.0 0.0 2.5 0.0 4.2 0.507 0.0 1.5 0.0 0.8 3.9 0.334 
Coactosin-like protein  COTL1_HUMAN 16 kDa 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Keratin, type I 
cytoskeletal 9  K1C9_HUMAN 62 kDa 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Calcyclin-binding protein  
CYBP_HUMAN 
(+1) 26 kDa 0.0 0.0 0.0 0.7 0.0 0.0 2.5 0.0 3.5 0.537 0.0 0.0 0.0 0.0 0.0 0.391 
Twinfilin-2  TWF2_HUMAN 40 kDa 0.0 0.0 0.6 1.5 0.0 0.0 1.1 0.0 0.5 0.597 0.0 0.8 0.0 1.7 1.2 0.876 
Astrocytic 
phosphoprotein PEA-15  PEA15_CRIGR 15 kDa 0.0 0.0 0.0 0.7 0.0 0.0 1.1 1.2 3.2 0.352 0.0 0.8 0.0 0.8 2.2 0.497 
PDZ and LIM domain 
protein 4  PDLI4_HUMAN 35 kDa 0.0 0.0 0.0 0.7 0.0 0.0 1.5 1.2 3.6 0.318 0.0 0.0 0.0 0.8 1.1 0.935 
Cofilin-2  
COF2_BOVIN 
(+1) 19 kDa 0.0 0.0 4.2 6.6 0.0 0.0 4.4 0.0 0.4 0.445 0.0 3.8 0.0 3.3 0.7 0.650 
60S ribosomal protein 
L21  
RL21_HUMAN 
(+1) 19 kDa 0.0 0.0 0.0 0.7 0.0 0.0 1.8 1.2 4.1 0.305 0.0 0.0 0.0 1.7 2.3 0.636 
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Weight 1 2 3 4 1 2 3 4 Fold   P-value 1 2 3 4 Fold   P-value 
UPF0556 protein 
C19orf10  CS010_HUMAN 19 kDa 0.0 0.0 0.6 0.0 0.6 0.0 1.5 0.0 3.3 0.401 0.0 1.5 0.0 0.0 2.5 0.607 
LIM domain and actin-
binding protein 1  LIMA1_HUMAN 85 kDa 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 N/A N/A 0.0 1.5 0.0 1.7 2.2 0.497 




specific form  
NACAM_MOUS
E 220 kDa 0.0 0.0 0.0 3.7 0.0 0.0 0.7 0.0 0.2 0.485 0.0 0.0 0.0 2.5 0.7 0.800 
Hemoglobin subunit 
beta-C(NA)  HBBN_AMMLE 16 kDa 10.9 0.0 0.0 0.0 0.0 4.3 0.0 0.0 0.4 0.605 0.0 0.0 0.0 0.0 N/A N/A 
Eukaryotic translation 
initiation factor 6  IF6_HUMAN 27 kDa 0.0 0.0 1.2 2.9 0.0 0.0 1.5 0.0 0.3 0.433 0.0 0.0 0.0 0.0 0.0 0.232 
Coatomer subunit delta  
COPD_HUMAN 
(+1) 57 kDa 0.0 0.0 0.0 3.7 0.0 0.0 1.8 0.0 0.5 0.671 0.0 0.8 0.0 0.0 0.2 0.490 
Phenylalanine--tRNA 




(+1) 80 kDa 0.0 0.0 0.6 0.0 0.0 0.0 3.6 0.0 6.0 0.469 0.0 0.0 0.0 0.0 N/A N/A 
Carbonyl reductase 
[NADPH] 1  
CBR1_HUMAN 
(+2) 30 kDa 0.0 0.0 0.0 0.0 0.0 0.0 3.3 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Bifunctional 
glutamate/proline--tRNA 
ligase  SYEP_HUMAN 171 kDa 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 N/A N/A 0.0 0.8 0.0 1.7 1.1 0.940 
Cystatin-C  CYTC_HUMAN 16 kDa 1.8 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.182 0.0 0.0 0.0 0.0 0.0 0.182 
ADP-ribosylation factor 
2  ARF2_BOVIN 21 kDa 0.0 1.1 0.0 2.2 0.0 0.0 1.5 0.0 0.4 0.492 0.0 0.8 0.0 0.0 0.2 0.318 
Serine/threonine-
protein phosphatase 5  PPP5_HUMAN 57 kDa 0.0 0.0 0.0 2.2 0.0 0.0 0.7 0.0 0.3 0.562 0.0 0.8 0.0 0.8 0.7 0.809 
26S proteasome non-
ATPase regulatory 
subunit 13  PSD13_HUMAN 43 kDa 0.0 0.0 0.0 0.7 0.0 0.0 0.7 0.0 1.0 0.993 0.0 0.8 0.0 0.8 2.2 0.497 
Growth-regulated alpha 
protein  GROA_HUMAN 11 kDa 0.0 1.1 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.187 0.0 1.5 0.0 0.0 0.6 0.630 
Ubiquitin-conjugating 
enzyme E2 L3  
UB2L3_BOVIN 
(+1) 18 kDa 0.0 0.0 0.6 0.0 0.0 0.0 1.8 0.0 3.0 0.565 0.0 0.0 0.0 0.8 1.4 0.835 
PDZ and LIM domain 
protein 1  PDLI1_HUMAN 36 kDa 0.0 0.0 0.0 0.7 0.0 0.0 1.8 0.0 2.5 0.611 0.0 0.0 0.0 0.0 N/A N/A 
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Weight 1 2 3 4 1 2 3 4 Fold  P-value 1 2 3 4 Fold   P-value 






(+1) 37 kDa 0.0 0.0 0.0 0.7 0.0 0.0 2.5 0.0 3.5 0.537 0.0 0.0 0.0 0.8 1.1 0.935 
Coatomer subunit alpha  
COPA_HUMAN 
(+1) 138 kDa 0.0 0.0 0.0 3.7 0.0 0.0 1.5 0.0 0.4 0.604 0.0 0.0 0.0 0.0 N/A N/A 
Eukaryotic translation 
initiation factor 3 
subunit E-A  EI3EA_XENLA 52 kDa 0.0 0.0 0.0 2.9 0.0 0.0 0.0 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Cytosol aminopeptidase  AMPL_HUMAN 56 kDa 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
PDZ and LIM domain 
protein 7  PDLI7_HUMAN 50 kDa 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Lysozyme C  
LYSC_HUMAN 
(+2) 17 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Neutrophil defensin 1  
DEF1_HUMAN 
(+2) 10 kDa 0.0 0.0 0.0 0.0 0.0 0.0 2.5 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 





(+6) 61 kDa 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 N/A N/A 0.0 1.5 0.0 0.8 N/A N/A 




[isomerizing] 1  GFPT1_HUMAN 79 kDa 0.0 0.0 0.0 0.7 0.0 0.0 0.7 0.0 1.0 0.993 0.0 0.0 0.0 1.7 2.3 0.636 
Hematological and 
neurological expressed 
1-like protein  HN1L_HUMAN 20 kDa 0.0 0.0 0.0 0.0 0.0 0.0 2.5 1.2 N/A N/A 0.0 0.0 0.0 0.8 N/A N/A 
ATP-binding cassette 
sub-family E member 1  ABCE1_HUMAN 67 kDa 0.0 0.0 0.0 2.2 0.0 0.0 1.1 1.2 1.1 0.966 0.0 0.0 0.0 0.0 0.0 N/A 
Eukaryotic translation 
initiation factor 4B  
IF4B_HUMAN 
(+1) 69 kDa 0.0 0.0 0.0 1.5 0.0 0.0 1.1 0.0 0.7 0.842 0.0 0.0 0.0 0.8 0.6 0.721 
Ran-specific GTPase-
activating protein  RANG_HUMAN 23 kDa 0.0 0.0 0.0 0.0 0.0 0.0 2.5 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Septin-2  
SEPT2_HUMAN 
(+2) 41 kDa 0.0 0.0 0.6 0.7 0.0 0.0 0.7 0.0 0.5 0.585 0.0 0.0 0.0 0.0 0.0 0.185 
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Weight 1 2 3 4 1 2 3 4 Fold   P-value 1 2 3 4 Fold   P-value 
Interleukin enhancer-
binding factor 3  
ILF3_HUMAN 
(+2) 95 kDa 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.391 0.0 0.8 0.0 0.0 0.3 0.571 
Protein phosphatase 1F  
PPM1F_HUMA




N 98 kDa 0.0 0.0 0.0 2.9 0.0 0.0 0.7 0.0 0.2 0.512 0.0 0.0 0.0 0.0 N/A N/A 
Complement 
component C9  CO9_BOVIN 62 kDa 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Clusterin  CLUS_BOVIN 51 kDa 0.0 0.0 0.0 0.0 3.9 0.0 0.0 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Actin-related protein 2/3 
complex subunit 3  
ARPC3_BOVIN 
(+1) 21 kDa 0.0 0.0 0.0 0.7 0.0 0.0 1.8 0.0 2.5 0.611 0.0 0.0 0.0 0.0 N/A N/A 
Uroporphyrinogen 
decarboxylase  DCUP_HUMAN 41 kDa 0.0 0.0 0.6 0.0 0.0 0.0 1.1 0.0 1.8 0.715 0.0 0.0 0.0 0.0 N/A N/A 
Keratin, type II 
cytoskeletal 4  K2C4_HUMAN 57 kDa 0.0 0.0 0.0 0.0 0.0 0.0 4.0 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Bifunctional purine 
biosynthesis protein 





1  AIMP1_HUMAN 34 kDa 0.0 0.0 0.0 0.7 0.0 0.0 0.7 0.0 1.0 0.993 0.0 0.0 0.0 0.8 1.1 0.935 
Mitogen-activated 
protein kinase 1  
MK01_HUMAN 
(+2) 41 kDa 0.0 0.0 0.6 0.7 0.0 0.0 1.8 1.2 2.3 0.437 0.0 0.0 0.0 0.0 0.0 0.185 
26S proteasome non-
ATPase regulatory 
subunit 1  
PSMD1_HUMA








(+4) 48 kDa 0.0 0.0 0.0 0.7 0.0 0.0 0.7 0.0 1.0 0.993 0.0 0.8 0.0 0.0 1.0 0.983 
Cullin-associated 
NEDD8-dissociated 
protein 1  
CAND1_BOVIN 




(+1) 32 kDa 0.0 0.0 0.0 3.7 0.0 0.0 0.0 0.0 N/A N/A 0.0 1.5 0.0 0.0 0.4 0.616 
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Weight 1 2 3 4 1 2 3 4 Fold  P-value 1 2 3 4 Fold   P-value 
Nucleosome assembly 
protein 1-like 1  
NP1L1_HUMAN 
(+2) 45 kDa 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Phosphoribosylformylgly
cinamidine synthase  PUR4_HUMAN 145 kDa 0.0 0.0 0.0 0.0 0.0 0.0 3.3 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Acyl-CoA-binding 
protein  ACBP_HUMAN 10 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Protein S100-A8  S10A8_HUMAN 11 kDa 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Complement C4-A  
CO4A_HUMAN 
(+1) 193 kDa 0.0 0.0 0.0 0.0 5.0 0.0 0.0 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Importin-7  
IPO7_HUMAN 
(+1) 120 kDa 0.0 0.0 0.0 2.2 0.0 0.0 0.7 1.2 0.9 0.925 0.0 0.0 0.0 0.8 0.4 0.592 
Guanine nucleotide-
binding protein G(i) 
subunit alpha-2  
GNAI2_HUMAN 
(+3) 40 kDa 0.0 1.1 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.212 0.0 2.3 0.0 0.0 0.7 0.743 
60S ribosomal protein 
L23  
RL23_AEDAE 
(+3) 15 kDa 0.0 0.0 0.0 0.7 0.0 0.0 0.7 0.0 1.0 0.993 0.0 0.0 0.0 0.0 N/A N/A 
Metalloproteinase 
inhibitor 1  
TIMP1_HUMAN 
(+2) 23 kDa 0.0 0.0 1.8 0.0 0.6 0.0 1.1 0.0 0.9 0.937 0.0 0.8 0.0 0.0 0.4 0.620 
ATP-dependent RNA 
helicase DDX3X  
DDX3X_HUMAN 
(+1) 73 kDa 0.0 0.0 0.6 0.7 0.0 0.0 1.8 0.0 1.4 0.822 0.0 0.0 0.0 0.0 0.0 0.185 
Nuclear autoantigenic 
sperm protein  NASP_HUMAN 85 kDa 0.0 0.0 0.0 0.7 0.0 0.0 0.7 0.0 1.0 0.993 0.0 0.0 0.0 0.0 N/A N/A 
Protein transport 
protein Sec31A  
SC31A_HUMAN 
(+1) 133 kDa 0.0 0.0 0.0 0.7 0.0 0.0 1.1 0.0 1.5 0.798 0.0 0.0 0.0 0.0 N/A N/A 
Switch-associated 
protein 70  
SWP70_HUMA
N 69 kDa 0.0 0.0 0.0 1.5 0.0 0.0 1.8 0.0 1.2 0.888 0.0 0.0 0.0 0.0 N/A N/A 
Rab GDP dissociation 





N 56 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Cytosolic acyl coenzyme 
A thioester hydrolase  BACH_HUMAN 42 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Adenosine kinase  ADK_HUMAN 41 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Plasma serine protease 
inhibitor  IPSP_BOVIN 45 kDa 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Aldose reductase  ALDR_HUMAN 36 kDa 0.0 0.0 0.0 0.7 0.0 0.0 1.8 0.0 2.5 0.611 0.0 0.8 0.0 0.0 1.0 0.983 
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Weight 1 2 3 4 1 2 3 4 Fold   P-value 1 2 3 4 Fold   P-value 
V-type proton ATPase 
catalytic subunit A  
VATA_HUMAN 
(+10) 68 kDa 0.0 0.0 0.0 2.2 0.0 0.0 0.4 0.0 0.2 0.467 0.0 0.0 0.0 0.0 N/A N/A 
Complement 
component 1 Q 
subcomponent-binding 
protein, mitochondrial  C1QBP_HUMAN 31 kDa 0.0 0.0 0.6 0.0 0.6 0.0 1.1 0.0 2.7 0.431 0.0 0.0 0.0 0.0 N/A N/A 
Interleukin enhancer-
binding factor 2  
ILF2_HUMAN 
(+1) 43 kDa 0.0 0.0 0.0 0.0 0.6 0.0 1.5 0.0 N/A 0.239 0.0 0.8 0.0 0.0 N/A N/A 
Leucine-rich repeat 
flightless-interacting 
protein 1  LRRF1_HUMAN 89 kDa 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 N/A N/A 0.0 1.5 0.0 0.8 3.2 0.376 
Filamin-binding LIM 
protein 1  
FBLI1_HUMAN 
(+1) 41 kDa 0.0 0.0 0.6 2.2 0.0 0.0 0.7 0.0 N/A N/A 0.0 0.0 0.0 0.0 0.0 0.270 
N-alpha-
acetyltransferase 15, 
NatA auxiliary subunit  
NAA15_HUMA
N (+2) 101 kDa 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.391 0.0 0.0 0.0 0.0 N/A N/A 
tRNA-splicing ligase RtcB 
homolog  
RTCB_HUMAN 
(+2) 55 kDa 0.0 0.0 0.0 2.9 0.0 0.0 0.7 0.0 0.2 0.512 0.0 0.0 0.0 0.8 0.3 0.533 
High mobility group 
protein B2  
HMGB2_BOVIN 
(+1) 24 kDa 0.0 0.0 0.0 3.7 0.0 0.0 0.4 0.0 0.1 0.435 0.0 0.0 0.0 0.8 0.2 0.500 
Sorting nexin-3  
SNX3_BOVIN 
(+1) 19 kDa 0.0 0.0 0.0 1.5 0.0 0.0 0.7 0.0 0.5 0.671 0.0 0.0 0.0 0.0 N/A N/A 
Cystatin-B  CYTB_GORGO 11 kDa 0.0 0.0 0.6 0.0 0.0 0.0 1.8 0.0 3.0 0.565 0.0 0.0 0.0 0.0 N/A N/A 
Cathepsin D  CATD_HUMAN 45 kDa 0.0 0.0 0.0 0.7 0.0 0.0 1.1 0.0 1.5 0.798 0.0 0.0 0.0 0.0 N/A N/A 
Heparin cofactor 2  
HEP2_MOUSE 
(+1) 54 kDa 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Platelet-activating factor 
acetylhydrolase IB 
subunit alpha  
LIS1_BOVIN 
(+5) 47 kDa 0.0 0.0 0.0 2.2 0.0 0.0 0.7 0.0 0.3 0.562 0.0 0.0 0.0 0.0 N/A N/A 
Eukaryotic translation 
initiation factor 3 
subunit H  EIF3H_HUMAN 40 kDa 0.0 0.0 0.0 2.9 0.0 0.0 0.0 0.0 N/A N/A 0.0 0.0 0.0 0.8 0.3 0.533 
Adenylate kinase 
isoenzyme 1  
KAD1_HUMAN 
(+3) 22 kDa 0.0 0.0 0.6 0.0 0.0 0.0 2.5 0.0 4.2 0.507 0.0 0.0 0.0 0.0 N/A N/A 
Ig alpha-1 chain C region  
IGHA1_HUMAN 
(+1) 38 kDa 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
60S ribosomal protein 
L35  
RL35_HUMAN 
(+7) 15 kDa 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
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Weight 1 2 3 4 1 2 3 4 Fold   P-value 1 2 3 4 Fold   P-value 
Inositol 
monophosphatase 1  
IMPA1_HUMAN 
(+1) 30 kDa 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 N/A N/A 0.0 0.0 0.0 0.8 N/A N/A 
60S ribosomal protein 
L24  RL24_BOVIN 18 kDa 0.0 0.0 0.0 0.7 0.0 0.0 1.1 0.0 1.5 0.798 0.0 0.0 0.0 0.8 1.1 0.935 
Collagen alpha-2(I) chain  CO1A2_BOVIN 129 kDa 0.0 0.0 0.0 0.0 1.1 0.0 0.7 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Signal recognition 
particle 9 kDa protein  
SRP09_HUMAN 
(+1) 10 kDa 0.0 0.0 0.6 0.0 0.0 0.0 1.5 0.0 2.4 0.619 0.0 0.8 0.0 0.0 1.3 0.879 
Gamma-interferon-
inducible protein 16  IF16_HUMAN 88 kDa 0.0 0.0 0.0 2.9 0.0 0.0 0.0 1.2 0.4 0.620 0.0 0.0 0.0 0.0 N/A N/A 
Lumican  LUM_BOVIN 39 kDa 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Tight junction protein 
ZO-2  ZO2_CANFA 132 kDa 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 












mitochondrial  DUT_HUMAN 27 kDa 0.0 0.0 0.0 0.7 0.0 0.0 1.1 0.0 1.5 0.798 0.0 0.0 0.0 0.0 N/A N/A 
UTP--glucose-1-
phosphate 
uridylyltransferase  UGPA_HUMAN 57 kDa 0.0 0.0 0.0 0.7 0.0 0.0 1.5 0.0 2.0 0.680 0.0 0.0 0.0 0.0 N/A N/A 
Dynactin subunit 2  
DCTN2_HUMA
N 44 kDa 0.0 0.0 0.0 1.5 0.0 0.0 0.7 0.0 0.5 0.671 0.0 0.0 0.0 0.0 N/A N/A 
ATP-dependent RNA 
helicase DDX1  
DDX1_HUMAN 
(+5) 82 kDa 0.0 0.0 0.0 2.2 0.0 0.0 0.4 0.0 0.2 0.467 0.0 0.0 0.0 0.0 N/A N/A 
Niban-like protein 1  NIBL1_HUMAN 84 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Keratin, type II 
cytoskeletal 5  K2C5_HUMAN 62 kDa 0.0 0.0 0.0 0.0 0.0 0.0 6.5 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Myeloperoxidase  PERM_HUMAN 84 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Spermidine synthase  SPEE_HUMAN 34 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
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N (+1) 24 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Deleted in malignant 
brain tumors 1 protein  
DMBT1_HUMA
N 261 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Coronin-1B  COR1B_PONAB 54 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Lipocalin-1  LCN1_HUMAN 19 kDa 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
UV excision repair 
protein RAD23 homolog 
A  RD23A_HUMAN 40 kDa 0.0 0.0 0.0 0.7 0.0 0.0 0.7 0.0 1.0 0.993 0.0 0.0 0.0 0.0 N/A N/A 
Mannose-1-phosphate 
guanyltransferase beta  
GMPPB_HUMA
N (+2) 40 kDa 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 N/A N/A 0.0 0.0 0.0 0.8 0.4 0.592 
Heme-binding protein 2  HEBP2_HUMAN 23 kDa 0.0 0.0 0.0 1.5 0.0 0.0 0.4 0.0 0.2 0.512 0.0 0.0 0.0 0.0 N/A N/A 
Actin, clone 302 
(Fragment)  ACT3_ARTSX 37 kDa 0.0 0.0 57.5 0.0 17.7 0.0 53.0 0.0 1.2 0.868 0.0 0.0 0.0 0.0 N/A N/A 
DNA replication licensing 
factor MCM6  MCM6_HUMAN 93 kDa 0.0 0.0 0.0 1.5 0.0 0.0 0.4 0.0 0.2 0.512 0.0 0.0 0.0 0.0 N/A N/A 
DNA damage-binding 
protein 1  
DDB1_HUMAN 
(+7) 127 kDa 0.0 0.0 0.0 1.5 0.0 0.0 0.4 0.0 0.2 0.512 0.0 0.0 0.0 0.0 N/A N/A 
Eukaryotic translation 
initiation factor 3 
subunit I  
EIF3I_HUMAN 
(+2) 37 kDa 0.0 0.0 0.0 2.2 0.0 0.0 0.4 0.0 0.2 0.467 0.0 0.0 0.0 0.0 N/A N/A 
Eukaryotic peptide chain 
release factor subunit 1  
ERF1_BOVIN 
(+2) 49 kDa 0.0 0.0 0.0 0.7 0.0 0.0 1.1 0.0 1.5 0.798 0.0 0.0 0.0 0.0 N/A N/A 
Alcohol dehydrogenase 
[NADP(+)]  AK1A1_HUMAN 37 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
CD44 antigen  CD44_HUMAN 82 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
CAD protein  
PYR1_HUMAN 




(+1) 47 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Calpain-1 catalytic 
subunit  CAN1_HUMAN 82 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Ig kappa chain C region  IGKC_HUMAN 12 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Adenylosuccinate 
synthetase isozyme 2  
PURA2_HUMA
N 50 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
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Weight 1 2 3 4 1 2 3 4 Fold  P-value 1 2 3 4 Fold   P-value 
Prefoldin subunit 2  
PFD2_HUMAN 
(+1) 17 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Serine/threonine-
protein phosphatase 2A 
65 kDa regulatory 
subunit A alpha isoform  
2AAA_HUMAN 
(+1) 65 kDa 0.0 0.0 0.0 0.7 0.0 0.0 0.7 0.0 1.0 0.993 0.0 0.0 0.0 0.0 N/A N/A 
N-acetyl-D-glucosamine 
kinase  NAGK_HUMAN 37 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Nucleophosmin  NPM_HUMAN 33 kDa 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 N/A N/A 0.0 0.0 0.0 1.7 0.8 0.850 
Nucleobindin-1  
NUCB1_HUMA
N (+2) 54 kDa 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Proteasome activator 
complex subunit 1  
PSME1_HUMA
N (+2) 29 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Farnesyl pyrophosphate 




N 53 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
A-kinase anchor protein 
2  AKAP2_HUMAN 95 kDa 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Polyadenylate-binding 
protein 4  PABP4_HUMAN 71 kDa 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Ran GTPase-activating 
protein 1  RAGP1_HUMAN 64 kDa 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 N/A N/A 0.0 0.0 0.0 0.8 0.6 0.721 
EH domain-containing 
protein 4  EHD4_HUMAN 61 kDa 0.0 0.0 0.0 0.7 0.0 0.0 0.7 0.0 1.0 0.993 0.0 0.0 0.0 0.0 N/A N/A 
Cold shock domain-




protein 1  
KHDR1_HUMA
N (+2) 48 kDa 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 N/A N/A 0.0 1.5 0.0 0.0 N/A N/A 
26S proteasome non-
ATPase regulatory 
subunit 6  
PSMD6_HUMA
N 46 kDa 0.0 0.0 0.0 1.5 0.0 0.0 0.7 0.0 0.5 0.671 0.0 0.0 0.0 0.0 N/A N/A 
Spleen trypsin inhibitor I  BPT2_BOVIN 11 kDa 0.0 0.0 0.6 0.0 1.7 0.0 0.0 0.0 2.7 0.584 0.0 0.0 0.0 0.0 N/A N/A 
Ribosome-binding 
protein 1  RRBP1_HUMAN 152 kDa 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
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Weight 1 2 3 4 1 2 3 4 Fold   P-value 1 2 3 4 Fold   P-value 
Small nuclear 
ribonucleoprotein Sm 
D3  SMD3_HUMAN 14 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
S-methyl-5'-
thioadenosine 
phosphorylase  MTAP_HUMAN 31 kDa 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Ribosome maturation 
protein SBDS  SBDS_HUMAN 29 kDa 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Polypyrimidine tract-
binding protein 1  
PTBP1_HUMAN 
(+4) 57 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Cytoplasmic dynein 1 
light intermediate chain 
1  DC1L1_HUMAN 57 kDa 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Cysteine--tRNA ligase, 
cytoplasmic  SYCC_HUMAN 85 kDa 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
ATP-dependent DNA 
helicase Q1  
RECQ1_HUMAN 
(+1) 73 kDa 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Eukaryotic translation 
initiation factor 1b  
EIF1B_HUMAN 
(+2) 13 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Prolactin-inducible 
protein  PIP_HUMAN 17 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Azurocidin  CAP7_HUMAN 27 kDa 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Sorting nexin-6  
SNX6_HUMAN 
(+2) 47 kDa 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Alcohol dehydrogenase 
class-3  ADHX_HUMAN 40 kDa 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
HLA class I 
histocompatibility 
antigen, B-73 alpha 
chain  
1B73_HUMAN 
(+4) 40 kDa 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Vasodilator-stimulated 
phosphoprotein  VASP_HUMAN 40 kDa 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
cAMP-regulated 
phosphoprotein 19  
ARP19_HUMAN 
(+3) 12 kDa 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Periostin  POSTN_HUMAN 93 kDa 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Transcription elongation 
factor B polypeptide 2  
ELOB_HUMAN 
(+1) 13 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
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Weight 1 2 3 4 1 2 3 4 Fold   P-value 1 2 3 4 Fold   P-value 
Serum deprivation-
response protein  SDPR_HUMAN 47 kDa 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 




(+4) 22 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Keratin, type I 
cytoskeletal 14  K1C14_HUMAN 52 kDa 0.0 0.0 0.0 0.0 0.0 0.0 6.2 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Acidic mammalian 
chitinase  CHIA_BOVIN 52 kDa 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Actin-related protein 2/3 
complex subunit 5-like 
protein  
ARP5L_HUMAN 
(+3) 17 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Glucosamine-6-
phosphate isomerase 1  
GNPI1_HUMAN 
(+1) 33 kDa 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Eukaryotic translation 
initiation factor 4 
gamma 1  
IF4G1_HUMAN 
(+1) 175 kDa 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Prefoldin subunit 5  PFD5_HUMAN 17 kDa 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Adapter molecule crk  
CRK_HUMAN 
(+2) 34 kDa 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
Major vault protein  
MVP_HUMAN 
(+3) 99 kDa 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 N/A N/A 0.0 0.0 0.0 0.0 N/A N/A 
 
P values were derived from unpaired Student t tests with unequal variance. 
"NA" denotes "not applicable"  
(note that every time protein expression in the majority of samples from 1 of the 2 groups compared was undetectable, the t test was not performed)  
Supplementary Figure 1. Distribution of tuning parameters λ1 from ten 
thousand 5-fold likelihood cross-validations of penalized logistic regression of 
associations of serum miRNA concentrations with incidence and progression 









The median lambda value was 4.60 in PREVENT-1 and 14.21 in PROTECT-1. 
Supplementary Figure 2. Association of miRNAs with diabetic retinopathy, adjusted for age, sex and diastolic blood pressure. 
 
 (A) PREVENT-1  (B) PROTECT-1 
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Supplementary Figure 3. Sensitivity analysis of the penalized logistic 
regression analysis of the association of serum miRNA concentrations 





(A) Standardizing Ct values to the global Ct average  












Supplementary Figure 4. Comparison of normalised serum 
concentrations of miR-27b and miR-320a. The plot depicts 
concentrations for individual participants (in green), plus a summary 





Supplementary Figure 5. Added predictive value of miR-27b and miR-













Standard risk markers subsume age, sex, duration of diabetes, diastolic blood pressure, and 
level of HbA1c. The areas under the curve for standard risk markers and standard risk 
markers plus miR-27b and miR320a were 0.662 (95% CI: 0.566, 0.757) and 0.749 (0.663, 
0.835) for PREVENT-1 (Δ 0.087, P=0.027), and 0.634 (95% CI: 0.551, 0.712) and 0.668 
(0.558, 0.748) for PREVENT-1 (Δ 0.034, P=0.214).  
 
 
 
 
 
 
